

FOR OFFICIAL USE ONLY

ACCESS DB #
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: JANE ZARA Examiner #: 77512 Date: 11-1-05
Art Unit: 1635 Phone Number: 2-0765 Serial Number: 09/699,667
Location (Bldg/Room#): 2D28 (Mailbox #): 2C12 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: NA enzyme
Inventors (please provide full names): J-P Perreault et al.

Earliest Priority Date: 4-29-99

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search Seq ID Nos:

62, 65, 66

- Limit to ~~200~~ 200 NTS
- No size limits
- Please include interference searches.

Thanks

STAFF USE ONLY

Type of Search		Vendors and cost where applicable	
Searcher: _____	____ NA Sequence (#)	____ STN	____ Dialog
Searcher Phone #: _____	____ AA Sequence (#)	____ Questel/Orbit	____ Lexis/Nexis
Searcher Location: _____	____ Structure (#)	____ Westlaw	____ WWW/Internet
Date Searcher Picked Up: _____	____ Bibliographic	____ In-house sequence systems	
Date Completed: _____	____ Litigation	____ Commercial	____ Oligomer
Searcher Prep & Review Time: _____	____ Fulltext	____ Interference	____ SPDI
Online Time: _____	____ Other	____ Other (specify)	

THIS PAGE BLANK (USPTO)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Bib Data Sheet

SERIAL NUMBER 09/699,867	FILING DATE 10/30/2000 RULE -	CLASS 435	GROUP ART UNIT 1635	ATTORNEY DOCKET NO. 77473-12
APPLICANTS Jean-Pierre Perreault, Fleurimont, CANADA; Sirinart Ananvoranich, Westbury, CANADA; Daniel Lafontaine, Saint-Alexis de Montcalm, CANADA.				
** CONTINUING DATA ***** THIS APPLICATION IS A CON OF PCT/CA99/00391 04/29/1999				
** FOREIGN APPLICATIONS ***** CANADA 2230203 04/29/1998				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 01/19/2001				
** SMALL ENTITY **				
Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY CANADA	SHEETS DRAWING 7	TOTAL CLAIMS 19	INDEPENDENT CLAIMS 1
ADDRESS 22249				
TITLE Nucleic acid enzyme for RNA cleavage				
FILING FEE RECEIVED 420	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			
				<input type="checkbox"/> All Fees
				<input type="checkbox"/> 1.16 Fees (Filing)
				<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
				<input type="checkbox"/> 1.18 Fees (Issue)
				<input type="checkbox"/> Other _____
				<input type="checkbox"/> Credit

THIS PAGE BLANK (USPTO)

CRF

10/26 0610 40

769207

10/27 45

10/28 20

SEARCH REQUEST FORM

Thanks.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 29, 2005, 08:49:56 ; Search time 792 Seconds
(without alignments)
594.397 Million cell updates/sec

Title: US-09-699-667E-61

Perfect score: 57
Sequence: 1 ggguccaccuccgcggun.....uucgaugcguaaggagccc 57

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 9784742 seqs, 4129495052 residues

Total number of hits satisfying chosen parameters: 11492560

Minimum DB seq length: 0

Maximum DB seq length: 150

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications NA.*

1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq.*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq.*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq.*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq.*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq.*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq.*
9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq.*
10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq.*
11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq.*
12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
13: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq.*
14: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq.*
15: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq.*
16: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq.*
17: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq.*
18: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq.*
19: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq.*
20: /cgn2_6/ptodata/1/pubpna/US10G_PUBCOMB.seq.*
21: /cgn2_6/ptodata/1/pubpna/US10H_PUBCOMB.seq.*
22: /cgn2_6/ptodata/1/pubpna/US10I_PUBCOMB.seq.*
23: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq.*
24: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq.*
25: /cgn2_6/ptodata/1/pubpna/US11A_PUBCOMB.seq.*
26: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq.*
27: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq.*
28: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24.4	42.8	52	18	US-10-346-880-40
2	24.4	42.8	52	18	US-10-346-880-80
3	24.4	42.8	52	18	US-10-150-407-40
4	24.4	42.8	52	18	US-10-150-407-80
5	24.4	42.8	90	9	US-09-733-042-12
					Sequence 40, Appl
					Sequence 80, Appl
					Sequence 40, Appl
					Sequence 80, Appl
					Sequence 12, Appl

ALIGNMENTS

RESULT 1
US-10-346-880-40
; Sequence 40, Application US/10346880
; Publication No. US20030232035A1
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr., Thomas W
; APPLICANT: Polo, John M
; APPLICANT: Ibanez, Carlos E
; APPLICANT: Chang, Stephen M.W.
; APPLICANT: Jolly, Douglas J
; APPLICANT: Driver, David A
; APPLICANT: Belli, Barbara A
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; FILE REFERENCE: EP01146.213 (CHIR-1146/11US)
; CURRENT APPLICATION NUMBER: US/10/346,880
; CURRENT FILING DATE: 2003-01-16
; PRIOR APPLICATION NUMBER: 09/503,138
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 09/191,747
; PRIOR FILING DATE: 1998-11-12
; PRIOR APPLICATION NUMBER: 08/739,199
; PRIOR FILING DATE: 1996-10-30
; PRIOR APPLICATION NUMBER: 08/404,796
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: 08/376,184
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: 08/348,472
; PRIOR FILING DATE: 1994-11-30

Sequence 13, Appl
Sequence 2, Appl
Sequence 7, Appl
Sequence 8, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 25, Appl
Sequence 163015,
Sequence 5, Appl
Sequence 1234, Ap
Sequence 9, Appl
Sequence 38, Appl
Sequence 38, Appl
Sequence 6071, Ap
Sequence 13039, A
Sequence 98, Appl
Sequence 7012, Ap
Sequence 32, Appl
Sequence 2147, Ap
Sequence 10, Appl
Sequence 10, Appl
Sequence 21127, A
Sequence 102935,
Sequence 10, Appl
Sequence 10629, A
Sequence 20125, A
Sequence 5, Appl
Sequence 1, Appl
Sequence 7614, Ap
Sequence 16350, A
Sequence 26097, A
Sequence 4898, Ap
Sequence 5007, Ap
Sequence 11299, A
Sequence 6, Appl
Sequence 163, App
Sequence 3957, Ap
Sequence 10, Appl
Sequence 11, Appl

;; PRIOR APPLICATION NUMBER: 08/198,450
;; PRIOR FILING DATE: 1994-02-18
;; PRIOR APPLICATION NUMBER: 08/122,791
;; PRIOR FILING DATE: 1993-09-15
;; NUMBER OF SEQ ID NOS: 128
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 40
;; LENGTH: 52
;; TYPE: DNA
;; ORGANISM: Unknown
;; FEATURES:
;; OTHER INFORMATION: Artificial sequence: nested primer HDV17-68
US-10-346-880-40

Query Match 42.8%; Score 24.4; DB 18; Length 52;
Best Local Similarity 59.4%; Pred. No. 17;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCUCGCGGNNNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGTCCGACCTGGGCATCCG 32

RESULT 2
US-10-346-880-80
;; Sequence 80, Application US/10346880
;; Publication No. US20030232035A1
;; GENERAL INFORMATION:
;; APPLICANT: Dubensky Jr., Thomas W
;; APPLICANT: Polo, John M
;; APPLICANT: Ibanez, Carlos E
;; APPLICANT: Chang, Stephen M.W.
;; APPLICANT: Jolly, Douglas J
;; APPLICANT: Driver, David A
;; APPLICANT: Belli, Barbara A
;; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
;; FILE REFERENCE: PP01146.213 (CHIR-1146/11US)
;; CURRENT APPLICATION NUMBER: US/10/346,880
;; CURRENT FILING DATE: 2003-01-15
;; PRIOR APPLICATION NUMBER: 09/503,138
;; PRIOR FILING DATE: 2000-02-11
;; PRIOR APPLICATION NUMBER: 09/191,747
;; PRIOR FILING DATE: 1998-11-12
;; PRIOR APPLICATION NUMBER: 08/739,199
;; PRIOR FILING DATE: 1996-10-30
;; PRIOR APPLICATION NUMBER: 08/404,796
;; PRIOR FILING DATE: 1995-03-15
;; PRIOR APPLICATION NUMBER: 08/376,184
;; PRIOR FILING DATE: 1995-01-18
;; PRIOR APPLICATION NUMBER: 08/348,472
;; PRIOR FILING DATE: 1994-11-30
;; PRIOR APPLICATION NUMBER: 08/198,450
;; PRIOR FILING DATE: 1994-02-18
;; PRIOR APPLICATION NUMBER: 08/122,791
;; PRIOR FILING DATE: 1993-09-15
;; NUMBER OF SEQ ID NOS: 128
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 80
;; LENGTH: 52
;; TYPE: DNA
;; ORGANISM: Unknown
;; FEATURES:
;; OTHER INFORMATION: Artificial sequence: reverse primer HKV17-68
US-10-346-880-80

Query Match 42.8%; Score 24.4; DB 18; Length 52;
Best Local Similarity 59.4%; Pred. No. 17;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCUCGCGGNNNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGTCCGACCTGGGCATCCG 32

RESULT 3
US-10-150-407-40
;; Sequence 40, Application US/10150407
;; Publication No. US20040029278A1
;; GENERAL INFORMATION:
;; APPLICANT: Dubensky Jr, Thomas W
;; Polo, John M.
;; Jolly, Douglas J.
;; Driver, David A.
;; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
;; NUMBER OF SEQUENCES: 128
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: SEED and BERRY LLP
;; STREET: 6300 Columbia Center, 701 Fifth Avenue
;; CITY: Seattle
;; STATE: Washington
;; COUNTRY: US
;; ZIP: 98104-7092
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/10/150,407
;; FILING DATE: 17-May-2002
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/09/350,522
;; FILING DATE: 08-Jul-1999
;; ATTORNEY/AGENT INFORMATION:
;; NAME: McMasters, David D.
;; REGISTRATION NUMBER: 33,963
;; REFERENCE/DOCKET NUMBER: 930049.423D1 / 1146.010
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (206) 622-4900
;; TELEFAX: (206) 682-6031
;; INFORMATION FOR SEQ ID NO: 40:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 52 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; SEQUENCE DESCRIPTION: SEQ ID NO: 40:
US-10-150-407-40
Query Match 42.8%; Score 24.4; DB 18; Length 52;
Best Local Similarity 59.4%; Pred. No. 17;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
Qy 4 UCCACCUCUCGCGGNNNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGTCCGACCTGGGCATCCG 32
RESULT 4
US-10-150-407-80
;; Sequence 80, Application US/10150407
;; Publication No. US20040029278A1
;; GENERAL INFORMATION:
;; APPLICANT: Dubensky Jr, Thomas W
;; Polo, John M.
;; Jolly, Douglas J.
;; Driver, David A.
;; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
;; NUMBER OF SEQUENCES: 128
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: SEED and BERRY LLP
;; STREET: 6300 Columbia Center, 701 Fifth Avenue
;; CITY: Seattle
;; STATE: Washington
;; COUNTRY: US


```
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/150,407
; FILING DATE: 17-May-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/350,522
; FILING DATE: 08-Jul-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423D1 / 1146.010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-10-150-407-80

Query Match 42.8%; Score 24.4; DB 18; Length 52;
Best Local Similarity 59.4%; Pred. No. 17;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 5
US-09-733-042-12
; Sequence 12, Application US/09733042
; Patent No. US20020168709A1
; GENERAL INFORMATION:
; APPLICANT: Hennecke, Frank
; TITLE OF INVENTION: Replicon Based Activation of Endogenous Genes
; FILE REFERENCE: 1700.0100001
; CURRENT APPLICATION NUMBER: US/09/733,042
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 60/169,988
; PRIOR FILING DATE: 1999-12-10
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 90
; TYPE: DNA
; ORGANISM: HDV-FOR
US-09-733-042-12

Query Match 42.8%; Score 24.4; DB 9; Length 90;
Best Local Similarity 59.4%; Pred. No. 16;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNUGGCAUGCG 35
Db 22 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 53

RESULT 6
US-09-733-042-13/c
; Sequence 13, Application US/09733042
; Patent No. US20020168709A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Hennecke, Frank
; APPLICANT: Renner, Wolfgang A.
; TITLE OF INVENTION: Replicon Based Activation of Endogenous Genes
; FILE REFERENCE: 1700.0100001
; CURRENT APPLICATION NUMBER: US/09/733,042
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 60/169,988
; PRIOR FILING DATE: 1999-12-10
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 13
; LENGTH: 90
; TYPE: DNA
; ORGANISM: HDV-REV
US-09-733-042-13

Query Match 42.8%; Score 24.4; DB 9; Length 90;
Best Local Similarity 59.4%; Pred. No. 16;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNUGGCAUGCG 35
Db 73 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 42

RESULT 7
US-09-190-246-2
; Sequence 2, Application US/09190246
; Publication No. US20030180257A1
; GENERAL INFORMATION:
; APPLICANT: Parrington, Mark
; APPLICANT: Li, Xiaomao
; APPLICANT: Klein, Michel
; TITLE OF INVENTION: ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES
; FILE REFERENCE: Parrington et al.
; CURRENT APPLICATION NUMBER: US/09/190,246
; CURRENT FILING DATE: 1998-11-13
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 90
; TYPE: DNA
; ORGANISM: Semliki Forest virus
US-09-190-246-2

Query Match 42.8%; Score 24.4; DB 10; Length 90;
Best Local Similarity 59.4%; Pred. No. 16;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNUGGCAUGCG 35
Db 22 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 53

RESULT 8
US-10-237-302-7
; Sequence 7, Application US/10237302
; Publication No. US20030119182A1
; GENERAL INFORMATION:
; APPLICANT: Alphavax, Inc.
; APPLICANT: Jonathan F. Smith
; APPLICANT: Kurt I. Kamrud
; APPLICANT: Jonathan O. Rayner
; APPLICANT: Sergey A. Dryga
; APPLICANT: Ian J. Caley
; TITLE OF INVENTION: ALPHAVIRUS REPLICON VECTOR SYSTEMS
; FILE REFERENCE: 01113.000202
; CURRENT APPLICATION NUMBER: US/10/237,302
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: 60/317,722
; PRIOR FILING DATE: 2001-09-06
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: FastSeq for Windows Version 4.0
```



```

; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 163015
; LENGTH: 130
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_80243C.1
US-10-425-115-163015

Query Match      36.1%; Score 20.6; DB 21; Length 130;
Best Local Similarity 49.1%; Pred. NO. 4.5e+02;
Matches 28; Conservative 4; Mismatches 25; Indels 0; Gaps 0;

QY      1  GGGUCCACUCCUGCGGNNNNNNNUGGCAUGCGGCUUGCGCAUGGCUAAGGACCC 57
      ||| ||| : ||| : : ||| : : ||| : : ||| : : ||| : : ||| :
DB      112 GGGCGCACCATGTCGCGTCTTTTGTAGCAAGAGCTTCGCCACAGCGCGTGGGACGC 56

RESULT 14
US-10-430-562-5
; Sequence 5, Application US/10430562
; Publication No. US20050074760A1
; GENERAL INFORMATION:
; APPLICANT: Matulic-Adamic, Jasenka
; Beigelman, Leonid
; Karpelesky, Alexander
; Jarvis, Thale
; Usman, Nassim
; DiRenzo, Anthony
; Wincott, Francine
; TITLE OF INVENTION: ENZYMIC NUCLEIC ACIDS CONTAINING
; 5'-AND/OR 3'-CAP STRUCTURES
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/430,562
; FILING DATE: 06-May-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/632,882
; FILING DATE: April 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 217/226
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; OTHER INFORMATION: The letter "N" stands for
; any base.
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-430-562-5

```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 29, 2005, 06:16:15 ; Search time 1294 Seconds
(without alignments)
72.077 Million cell updates/sec

Title: US-09-699-667E-61

Perfect score: 57
Sequence: 1 ggguccaccuccgcggun.....uucgauggcuaaggacc 57

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 1367770

Minimum DB seq length: 0
Maximum DB seq length: 150

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA.*
1: /cgn2_6/ptodata/1/ina/5A COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PCTUS COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	25.8	45.3	61	1	US-08-238-963A-18
2	24.4	42.8	52	1	US-08-741-881-40
3	24.4	42.8	52	1	US-08-741-881-80
4	24.4	42.8	52	1	US-08-739-158-40
5	24.4	42.8	52	1	US-08-739-158-80
6	24.4	42.8	52	2	US-08-739-167-40
7	24.4	42.8	52	2	US-08-739-167-80
8	24.4	42.8	52	3	US-08-404-796-40
9	24.4	42.8	52	3	US-08-404-796-80
10	24.4	42.8	52	3	US-08-931-869-40
11	24.4	42.8	52	3	US-08-931-869-80
12	24.4	42.8	52	3	US-08-350-399-40
13	24.4	42.8	52	3	US-08-350-399-80
14	24.4	42.8	52	3	US-09-236-140A-40
15	24.4	42.8	52	3	US-09-236-140A-80
16	24.4	42.8	80	1	US-08-238-963A-16
17	24.4	42.8	83	3	US-08-646-695-12
18	24.4	42.8	83	5	PCT-US96-06053-12
19	24.4	42.8	84	1	US-08-238-963A-13
20	24.4	42.8	84	1	US-08-238-963A-14
21	24.4	42.8	86	1	US-08-238-963A-6
22	24.4	42.8	90	4	US-09-554-337-2
23	24.4	42.8	90	4	US-09-733-042-12
24	24.4	42.8	90	4	US-09-733-042-13
25	24.4	42.8	101	6	5225337-2
26	24.4	42.8	101	6	5225337-2
27	24.4	42.8	105	2	US-08-553-619B-25

Sequence 30, Appl
Sequence 12, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 39, Appl
Sequence 15, Appl
Sequence 5, Appl
Sequence 6, Appl
Sequence 1875, Ap
Sequence 373, App
Sequence 7, Appl
Sequence 5, Appl
Sequence 18, Appl
Sequence 1234, Ap

ALIGNMENTS

RESULT 1
US-08-238-963A-18
; Sequence 18, Application US/08238963A
; Patent No. 5625047
; GENERAL INFORMATION:
; APPLICANT: Been, Michael D.
; APPLICANT: Rosenstein, Sarah P.
; APPLICANT: Perrotta, Anne T.
; TITLE OF INVENTION: ENZYMAIC RNA MOLECULES
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/238,963A
; FILING DATE: May 5, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/821,155
; FILING DATE: January 13, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 207/093
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 61 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-238-963A-18

Query Match 45.3%; Score 25.8; DB 1; Length 61;
Best Local Similarity 77.4%; Pred. No. 1.4; Indels 4; Gaps 1;
Matches 41; Conservative 0; Mismatches 8;

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049,423C7 / 1146.008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-739-167-80

Query Match 42.8%; Score 24.4; DB 2; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 4 UCCACUCCUCCGGGNNNNNNUGGCGCAUGCG 35
DB 1 TCCACCTCTCCGGGTCGACCTGGGCATCCG 32

RESULT 8
US-08-404-796-40
; Sequence 40, Application US/08404796
; Patent No. 6015686
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.W.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 15-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049,423C5 / 1146.006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid

; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-404-796-40

Query Match 42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 4 UCCACUCCUCCGGGNNNNNNUGGCGCAUGCG 35
DB 1 TCCACCTCTCCGGGTCGACCTGGGCATCCG 32

RESULT 9
US-08-404-796-80
; Sequence 80, Application US/08404796
; Patent No. 6015686
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.W.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/404,796
; FILING DATE: 15-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049,423C5 / 1146.006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-404-796-80

Query Match 42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 4 UCCACUCCUCCGGGNNNNNNUGGCGCAUGCG 35
DB 1 TCCACCTCTCCGGGTCGACCTGGGCATCCG 32

RESULT 10
US-08-931-869-40
; Sequence 40, Application US/08931869
; Patent No. 6015694
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W

APPLICANT: Polo, John M.
APPLICANT: Ibanez, Carlos E.
APPLICANT: Chang, Stephen M.W.
APPLICANT: Jolly, Douglas J.
APPLICANT: Driver, David A.
APPLICANT: Belli, Barbara A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/931,869
FILING DATE: 16-SEP-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/404,796
FILING DATE: 15-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423C5 / 1146.006
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 52 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-931-869-40
Query Match 42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
QY 4 UCCACUCCUCCGGGCGGNNNNNNUGGCGAUGCG 35
Db 1 TCCACCTCTCGGGTCCGACCTGGCGATCCG 32
RESULT 11
US-08-931-869-80
Sequence 80, Application US/08931869
Patent No. 6015694
GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
APPLICANT: Polo, John M.
APPLICANT: Ibanez, Carlos E.
APPLICANT: Chang, Stephen M.W.
APPLICANT: Jolly, Douglas J.
APPLICANT: Driver, David A.
APPLICANT: Belli, Barbara A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/350,399
FILING DATE: 08-Jul-1999
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423D1 / 1146.010
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 52 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-931-869-40

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/931,869
FILING DATE: 16-SEP-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/404,796
FILING DATE: 15-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423C5 / 1146.006
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 80:
SEQUENCE CHARACTERISTICS:
LENGTH: 52 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-931-869-80
Query Match 42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
QY 4 UCCACUCCUCCGGGCGGNNNNNNUGGCGAUGCG 35
Db 1 TCCACCTCTCGGGTCCGACCTGGCGATCCG 32
RESULT 12
US-09-350-399-40
Sequence 40, Application US/09350399
Patent No. 6342372
GENERAL INFORMATION:
APPLICANT: Dubensky Jr, Thomas W
APPLICANT: Polo, John M.
APPLICANT: Jolly, Douglas J.
APPLICANT: Driver, David A.
TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/350,399
FILING DATE: 08-Jul-1999
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423D1 / 1146.010
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 52 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-931-869-80

```
;
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 40:
US-09-350-399-40

Query Match      42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCGCGGUNNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 13
US-09-350-399-80
; Sequence 80, Application US/09350399
; Patent No. 6342372
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; Polo, John M.
; Jolly, Douglas J.
; Driver, David A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/350,399
; FILING DATE: 08-Jul-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: McMaisters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423D1 / 1146.010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-09-350-399-80

Query Match      42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCGCGGUNNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 14
US-09-236-140A-40
; Sequence 40, Application US/09236140A
; Patent No. 6376236
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; Polo, John M.
```

```
;
; Ibanez, Carlos E.
; Chang, Stephen M.W.
; Jolly, Douglas J.
; Driver, David A.
; Belli, Barbara A.
; TITLE OF INVENTION: RECOMBINANT ALPHAVIRUS PARTICLES
; NUMBER OF SEQUENCES: 124
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OPPENHEIMER WOLFF & DONNELLY
; STREET: 840 NEWPORT CENTER DRIVE, SUITE 700
; CITY: NEWPORT BEACH
; STATE: CALIFORNIA
; COUNTRY: US
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/236,140A
; FILING DATE: 22-Jan-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Cullman, Louis C.
; REGISTRATION NUMBER: 39,645
; REFERENCE/DOCKET NUMBER: 20263.332 / 1146.020
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (949) 823.6000
; TELEFAX: (949) 823.6100
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 40:
US-09-236-140A-40

Query Match      42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCGCGGUNNNNNNUGGCAUGCG 35
Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 15
US-09-236-140A-80
; Sequence 80, Application US/09236140A
; Patent No. 6376236
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; Polo, John M.
; Ibanez, Carlos E.
; Chang, Stephen M.W.
; Jolly, Douglas J.
; Driver, David A.
; Belli, Barbara A.
; TITLE OF INVENTION: RECOMBINANT ALPHAVIRUS PARTICLES
; NUMBER OF SEQUENCES: 124
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OPPENHEIMER WOLFF & DONNELLY
; STREET: 840 NEWPORT CENTER DRIVE, SUITE 700
; CITY: NEWPORT BEACH
; STATE: CALIFORNIA
; COUNTRY: US
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```

; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/236.140A
; FILING DATE: 22-Jan-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Cullman, Louis C.
; REGISTRATION NUMBER: 39,645
; REFERENCE/DOCKET NUMBER: 20263.332 / 1146.020
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (949) 823.6000
; TELEFAX: (949) 823.6100
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 52 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-09-236-140A-80

```

```

Query Match          42.8%; Score 24.4; DB 3; Length 52;
Best Local Similarity 59.4%; Pred. No. 4.6;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

```

```

Qy      4 UCCACCUCCGCGGNNNNNNUGGCGAUGCG 35
       :|||||:|||||:|||||:
Db      1 TCCACCTCCTCGCGTCCGACCTGGCATCG 32

```

Search completed: October 29, 2005, 10:01:36
Job time : 1294 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 29, 2005, 01:27:07 ; Search time 451 Seconds
(without alignments)
748.171 Million cell updates/sec

Title: US-09-699-667E-61
Perfect score: 57
Sequence: 1 ggguccaccuccgcggun.....uucgcauggcuaagggacc 57

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues
Total number of hits satisfying chosen parameters: 4723312

Minimum DB seq length: 0
Maximum DB seq length: 150

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N Geneseq_16Dec04:*
1: Geneseqn1980s:*
2: Geneseqn1990s:*
3: Geneseqn2000s:*
4: Geneseqn2001as:*
5: Geneseqn2001bs:*
6: Geneseqn2002as:*
7: Geneseqn2002bs:*
8: Geneseqn2003as:*
9: Geneseqn2003bs:*
10: Geneseqn2003cs:*
11: Geneseqn2003ds:*
12: Geneseqn2004as:*
13: Geneseqn2004bs:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	51	89.5	57	3 AAZ57636	Aaz57636 Trans-act
2	51	89.5	57	3 AAZ57637	Aaz57637 Trans-act
3	41.4	72.6	57	3 AAZ57638	Aaz57638 Trans-act
4	29.4	51.6	37	3 AAZ57639	Aaz57639 Nucleotid
5	25.8	45.3	61	2 AAQ46667	Aaq46667 Substrate
6	24.4	42.8	48	13 ADRA7040	Adr47040 Dengue vi
7	24.4	42.8	48	13 ADT48985	Adt48985 PCR prime
8	24.4	42.8	51	2 AAQ86173	Aaq86173 Primer HD
9	24.4	42.8	52	2 AAQ86204	Aaq86204 Sindbis/H
10	24.4	42.8	52	2 AAT31151	Aat31151 HDV rever
11	24.4	42.8	52	2 AAT30817	Aat30817 HDV riboz
12	24.4	42.8	52	2 AAU42394	Aau42394 Nested PC
13	24.4	42.8	52	2 AAU42426	Aau42426 Forward P
14	24.4	42.8	52	2 AAV60154	Aav60154 Nested PC
15	24.4	42.8	52	2 AAV60185	Aav60185 Reverse P
16	24.4	42.8	52	2 AAV70746	Aav70746 Reverse P
17	24.4	42.8	52	2 AAV70714	Aav70714 Nested pr
18	24.4	42.8	52	3 AAZ92930	Aaz92930 Hepatitis
19	24.4	42.8	52	3 AAZ92970	Aaz92970 Hepatitis
20	24.4	42.8	52	3 AAZ92843	Aaz92843 Hepatitis

21	24.4	42.8	52	3 AAZ92803	Aaz92803 Hepatitis
22	24.4	42.8	52	6 AAL38850	Aal38850 Alphaviru
23	24.4	42.8	52	6 AAL38810	Aal38810 Alphaviru
24	24.4	42.8	52	6 ABK46276	Abk46276 HDV anti
25	24.4	42.8	52	6 ABK46316	Abk46316 Hepatitis
26	24.4	42.8	52	12 ADI30383	Adi30383 Hepatitis
27	24.4	42.8	52	12 ADI30423	Adi30423 Hepatitis
28	24.4	42.8	52	12 ADOI3982	Adoi3982 Eukaryoti
29	24.4	42.8	52	12 ADOI3942	Adoi3942 Eukaryoti
30	24.4	42.8	57	12 ADH10551	Adh10551 Hepatitis
31	24.4	42.8	80	2 AAQ53138	Aaq53138 Substrate
32	24.4	42.8	80	2 AAQ53140	Aaq53140 Substrate
33	24.4	42.8	83	5 AAF28121	Aaf28121 HDV riboz
34	24.4	42.8	84	13 ADR47033	Adr47033 Dengue vi
35	24.4	42.8	85	2 AAQ46665	Aaq46665 Self-clea
36	24.4	42.8	86	2 AAQ46663	Aaq46663 Self-clea
37	24.4	42.8	90	2 AAX76586	Aax76586 Hepatitis
38	24.4	42.8	90	5 AAF84035	Aaf84035 EPO gene
39	24.4	42.8	90	5 AAF84036	Aaf84036 EPO gene
40	24.4	42.8	91	8 AB282120	Abz82120 Hepatitis
41	24.4	42.8	94	12 ADP96249	Adp96249 HEP rabie
42	24.4	42.8	99	8 AB282121	Abz82121 Hepatitis
43	23	40.4	56	2 AAX59264	Aax59264 Nested pr
44	23	40.4	56	2 AAX58506	Aax58506 Nested pr
45	23	40.4	56	8 ABX81463	Abx81463 Sindbis v

ALIGNMENTS

RESULT 1
AAZ57636
ID AAZ57636 standard; RNA; 57 BP.
XX
AC AAZ57636;
XX
DT 05-APR-2000 (first entry)
XX
DE Trans-acting antigenomic delta ribozyme, deltaRzPl.1 nucleotide sequence.
XX
KW Trans-acting antigenomic delta ribozyme; viral RNA cleavage;
KW inherited disease; deltaRzPl.1; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_binding 1..6
FT /tag= a
FT /note= "Forms double stranded region with bases 52-57"
FT stem_loop 7..19
FT /tag= b
FT misc_binding 20..25
FT /tag= c
FT /bound moiety= "SP1.1 substrate (AAZ57641) bases 5-11"
FT stem_loop 30..45
FT /tag= d
FT misc_binding 52..57
FT /tag= e
FT /note= "Forms a double stranded region with bases 6-1"
XX
PN WO9955856-A2.
XX
PD 04-NOV-1999.
XX
PF 29-APR-1999; 99WO-CA000391.
XX
PR 29-APR-1998; 98CA-02230203.
PA (UYSH) UNIV SHERBROOKE.
PI Perreault J, Ananvoranich S, Lafontaine D;
DR WPI; 2000-096791/08.

```
XX
PT New construction of nucleic acid enzyme useful for biotechnological,
PT diagnostic and therapeutic applications.
XX
PS Example 1; Fig 1A; 52pp; English.
XX
CC This is the nucleotide sequence of ribozyme deltaRzP1.1. This ribozyme
CC cleaves substrate SP1.1 (see AA257641). The invention relates to a
CC nucleic acid enzyme (e.g. deltaRzP1.1) that is constructed to have a
CC substrate binding portion with the following sequence 3'-UNNXXN-5'. The
CC substrate of the enzyme has the sequence 5'-H*GNHNN-3'. The binding
CC portion of the enzyme (ribozyme) base pairs to 6 nucleotides 3' to the
CC cleavage site of the substrate (cleavage site is represented by *). At
CC least one nucleotide is present 5' to the cleavage site of the substrate
CC sequence. The enzyme of the invention is used to cleave a substrate
CC nucleotide sequence at a specific cleavage site by mixing the substrate
CC with the enzyme. The enzyme is used to cleave viral RNA or RNA causing
CC for example an inherited disease. The enzymes also have other
CC therapeutic, biotechnological and diagnostic applications
XX
SQ Sequence 57 BP; 7 A; 21 C; 19 G; 0 T; 10 U; 0 Other;

Query Match      89.5%; Score 51; DB 3; Length 57;
Best Local Similarity 89.5%; Pred. No. 9e-09;
Matches 51; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1 GGGUCCACCUCCGCGGNNNNNUGGCAUGCGGCUUGGCUAAGGGACCC 57
Db 1 GGGUCCACCUCCGCGGACCGGCAUGCGGCUUGGCUAAGGGACCC 57

RESULT 2
AAZ57637
ID AAZ57637 standard; RNA; 57 BP.
XX
AC AAZ57637;
XX
DT 05-APR-2000 (first entry)
XX
DE Trans-acting antigenomic delta ribozyme, deltaRzP1.2 nucleotide sequence.
XX
KW Trans-acting antigenomic delta ribozyme; viral RNA cleavage;
KW inherited disease; deltaRzP1.2; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_binding 1..6
FT /tag= a
FT /note= "Forms double stranded region with bases 52-57"
FT stem_loop 7..19
FT /tag= b
FT misc_binding 20..25
FT /tag= c
FT stem_loop 30..45
FT /tag= d
FT misc_binding 52..57
FT /tag= e
FT /note= "Forms a double stranded region with bases 6-1"
XX
FN WO9955856-A2.
XX
PD 04-NOV-1999.
XX
PF 29-APR-1999; 99WO-CA000391.
XX
PR 29-APR-1998; 98CA-02230203.
XX
PA (UYSH ) UNIV SHERBROOKE.
XX
PI Perreault J, Ananvoranich S, Lafontaine D;
XX
```

```
DR WPI; 2000-096791/08.
XX
PT New construction of nucleic acid enzyme useful for biotechnological,
PT diagnostic and therapeutic applications.
XX
PS Example 1; Page; 52pp; English.
XX
CC This is the nucleotide sequence of ribozyme deltaRzP1.2. This ribozyme
CC cleaves substrate SP1.2 (see AA257634). The invention relates to a
CC nucleic acid enzyme (e.g. deltaRzP1.2) that is constructed to have a
CC substrate binding portion with the following sequence 3'-UNNXXN-5'. The
CC substrate of the enzyme has the sequence 5'-H*GNHNN-3'. The binding
CC portion of the enzyme (ribozyme) base pairs to 6 nucleotides 3' to the
CC cleavage site of the substrate (cleavage site is represented by *). At
CC least one nucleotide is present 5' to the cleavage site of the substrate
CC sequence. The enzyme of the invention is used to cleave a substrate
CC nucleotide sequence at a specific cleavage site by mixing the substrate
CC with the enzyme. The enzyme is used to cleave viral RNA or RNA causing
CC for example an inherited disease. The enzymes also have other
CC therapeutic, biotechnological and diagnostic applications. Note: This
CC sequence is not shown in the specification, but has been derived from the
CC deltaRzP1.1 sequence (AA257636) shown in figure 1
XX
SQ Sequence 57 BP; 7 A; 21 C; 19 G; 0 T; 10 U; 0 Other;

Query Match      89.5%; Score 51; DB 3; Length 57;
Best Local Similarity 89.5%; Pred. No. 9e-09;
Matches 51; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1 GGGUCCACCUCCGCGGNNNNNUGGCAUGCGGCUUGGCUAAGGGACCC 57
Db 1 GGGUCCACCUCCGCGGCCAGCGGCAUGCGGCUUGGCUAAGGGACCC 57

RESULT 3
AAZ57638
ID AAZ57638 standard; RNA; 57 BP.
XX
AC AAZ57638;
XX
DT 15-SEP-2003 (revised)
DT 05-APR-2000 (first entry)
XX
DE Trans-acting antigenomic delta ribozyme nucleotide sequence.
XX
KW Trans-acting antigenomic delta ribozyme; viral RNA cleavage;
KW inherited disease; ss.
XX
OS Hepatitis D virus.
XX
FH Key Location/Qualifiers
FT misc_binding 1..6
FT /tag= a
FT /note= "Forms double stranded region with bases 52-57"
FT stem_loop 7..19
FT /tag= b
FT misc_binding 20..25
FT /tag= c
FT stem_loop 30..45
FT /tag= d
FT misc_binding 52..57
FT /tag= e
FT /note= "Forms a double stranded region with bases 6-1"
XX
FN WO9955856-A2.
XX
PD 04-NOV-1999.
XX
PF 29-APR-1999; 99WO-CA000391.
XX
PR 29-APR-1998; 98CA-02230203.
XX
```

```
PA (UYSH ) UNIV SHERBROOKE.
XX
XX Perreault J, Ananvoranich S, Lafontaine D;
XX
XX WPI; 2000-096791/08.
XX
XX New construction of nucleic acid enzyme useful for biotechnological,
XX diagnostic and therapeutic applications.
XX
XX Example 1; Fig 2; 52pp; English.
XX
XX This is the nucleotide sequence of a trans-acting antigenomic delta
XX ribozyme of the invention. This ribozyme cleaves substrate SPI.1 (see
XX AAZ57641). The invention relates to a nucleic acid enzyme (e.g.
XX deltaR2p1.1) that is constructed to have a substrate binding portion with
XX the following sequence 3'-UNNXNN-5'. The substrate of the enzyme has the
XX sequence 5'-H'*GNNHN-3'. The binding portion of the enzyme (ribozyme)
XX base pairs to 6 nucleotides 3' to the cleavage site of the substrate
XX (cleavage site is represented by *). At least one nucleotide is present
XX 5' to the cleavage site of the substrate sequence. The enzyme of the
XX invention is used to cleave a substrate nucleotide sequence at a specific
XX cleavage site by mixing the substrate with the enzyme. The enzyme is used
XX to cleave viral RNA or RNA causing for example an inherited disease. The
XX enzymes also have other therapeutic, biotechnological and diagnostic
XX applications. (Updated on 15-SEP-2003 to standardise OS field)
XX
XX Sequence 57 BP; 7 A; 21 C; 19 G; 0 T; 10 U; 0 Other;
XX
XX Query Match 72.6%; Score 41.4; DB 3; Length 57;
XX Best Local Similarity 78.9%; Pred. No. 2.6e-05;
XX Matches 45; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
XX
XX QY 1 GGGUCCACCUCUCCGGGUNNNNNNUGGCAUGCGGCUUGGCUAAGGACCC 57
XX |||||
XX Db 1 GGGUCCACCUCUCCGGGUGCCGACCGGCGGCAUGCCUUGCGGCAUGGCUAAGGACCC 57
XX |||||
XX
XX RESULT 4
XX AAZ57639
XX ID AAZ57639 standard; RNA; 37 BP.
XX
XX AC AAZ57639;
XX
XX 05-APR-2000 (first entry)
XX
XX Nucleotide sequence of bimolecular ribozyme RZA fragment.
XX
XX Bimolecular ribozyme; viral RNA cleavage; RZA fragment;
XX inherited disease; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_binding 1..6
XX /tag= a
XX /bound moiety= "RzB fragment of bimolecular ribozyme"
XX /note= "Forms double-stranded region with bases 20-16 of
XX sequence AAZ57640"
XX
XX stem_loop 7..19
XX /tag= b
XX /tag= c
XX /bound moiety= "Ribozyme substrate P1.1"
XX /note= "Forms double-stranded region with bases 11-6 of
XX sequence AAZ57641"
XX
XX misc_binding 30..37
XX /tag= d
XX /bound moiety= "RzB fragment of bimolecular ribozyme"
XX /note= "Forms double-stranded region with bases 8-1 of
XX sequence AAZ57640"
XX
XX W09955856-A2.
XX
XX
```

```
PD 04-NOV-1999.
XX
XX 29-APR-1999; 99WO-CA000391.
XX
XX 29-APR-1998; 98CA-02230203.
XX
XX (UYSH ) UNIV SHERBROOKE.
XX
XX Perreault J, Ananvoranich S, Lafontaine D;
XX
XX WPI; 2000-096791/08.
XX
XX New construction of nucleic acid enzyme useful for biotechnological,
XX diagnostic and therapeutic applications.
XX
XX Example 5; Fig 4; 52pp; English.
XX
XX This is the nucleotide sequence bimolecular ribozyme RZA fragment. This
XX ribozyme cleaves substrate SPI.1 (see AAZ57641). The invention relates to
XX a nucleic acid enzyme (e.g. deltaR2p1.1) that is constructed to have a
XX substrate binding portion with the following sequence 3'-UNNXNN-5'. The
XX substrate of the enzyme has the sequence 5'-H'*GNNHN-3'. The binding
XX portion of the enzyme (ribozyme) base pairs to 6 nucleotides 3' to the
XX cleavage site of the substrate (cleavage site is represented by *). At
XX least one nucleotide is present 5' to the cleavage site of the substrate
XX sequence. The enzyme of the invention is used to cleave a substrate
XX nucleotide sequence at a specific cleavage site by mixing the substrate
XX with the enzyme. The enzyme is used to cleave viral RNA or RNA causing
XX for example an inherited disease. The enzymes also have other
XX therapeutic, biotechnological and diagnostic applications
XX
XX Sequence 37 BP; 3 A; 16 C; 12 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 51.6%; Score 29.4; DB 3; Length 37;
XX Best Local Similarity 81.1%; Pred. No. 0.5;
XX Matches 30; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
XX
XX QY 1 GGGUCCACCUCUCCGGGUNNNNNNUGGCAUGCGGCUUGGCAUGGCGCC 37
XX |||||
XX Db 1 GGGUCCACCUCUCCGGGUGCCGACCGGCGGCAUGCCUUGCGGCAUGGCGCC 37
XX |||||
XX
XX RESULT 5
XX AAQ46667
XX ID AAQ46667 standard; RNA; 61 BP.
XX
XX AC AAQ46667;
XX
XX 25-MAR-2003 (revised)
XX 13-JAN-1994 (first entry)
XX
XX Substrate-cleaving sequence ADC3.
XX
XX Substrate; self-cleaving sequence; HDV; hepatitis delta virus; enzyme;
XX duplex; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX stem_loop 7..55
XX /tag= a
XX
XX misc_structure 7..10
XX /tag= b
XX /label= stem II
XX /note= "forms duplex with region 52..55"
XX
XX stem_loop 11..23
XX /tag= d
XX
XX misc_structure 11..13
XX /tag= e
XX /label= stem III
XX /note= "forms duplex with region 21..23"
XX
XX misc_feature 21..23
XX /tag= f
XX
```

```

FT FT /label= stem_III
FT FT /note= "forms duplex with region 11. .13"
FT FT 24. .30
FT FT /*tag= g
FT FT /note= "RNA substrate binding region"
FT FT 33. .37
FT FT /*tag= i
FT FT /label= stem_IV
FT FT /note= "forms duplex with region 42. .45"
FT FT 34. .45
FT FT /*tag= h
FT FT 42. .45
FT FT /*tag= j
FT FT /label= stem_IV
FT FT /note= "forms duplex with region 33. .37"
FT FT 52. .55
FT FT /*tag= c
FT FT /label= stem_II
FT FT /note= "forms duplex with region 7. .10"
FT FT
XX XX WO9314218-A1.
XX XX 22-JUL-1993.
XX PF 12-JAN-1993; 93WO-US000292.
XX PF 13-JAN-1992; 92US-00821155.
XX XX (UYDU-) UNIV DUKE.
XX XX Been MD, Rosenstein SP, Perrota AT;
XX XX WPI; 1993-243233/30.
XX XX
XX FT Nucleic acid molecule having RNA substrate-cleaving enzymatic activity -
XX FT useful for cleaving specific target molecules in-vitro.
XX PS Disclosure; Fig 8; 55pp; English.
XX CC The self-cleaving sequences from genomic and antigenomic HDV can be used
XX CC to develop enzymatic RNA mols. with similar properties. ADC3 is a smaller
XX CC version of ADC1 (AAQ53138), wherein stem IV is shortened. Such a smaller
XX CC enzymatic RNA has simplified synthesis and the potential for higher
XX CC specific activity due to a higher probability that a small RNA will fold
XX CC into an enzymatically active structure. (Updated on 25-MAR-2003 to
XX CC correct PN field.)
XX SQ Sequence 61 BP; 10 A; 20 C; 19 G; 0 T; 12 U; 0 Other;
XX
Query Match 45.3%; Score 25.8; DB 2; Length 61;
Best Local Similarity 77.4%; Pred. No. 11;
Matches 41; Conservative 0; Mismatches 8; Indels 4; Gaps 1;
Qy 4 UCCACCUCCUGCGGNNNNNUGGCAUGCGGCUUGCGCAUGGCUAAGGGACC 56
Db 8 UCCACCUCCUGCGGCUUGCGGCAU-----CUUCGGAUGGCUAAGGGAGC 56
RESULT 6
AD47040
ID ADR47040 standard; DNA; 48 BP.
XX AC ADR47040;
XX XX
DT 18-NOV-2004 (first entry)
XX XX Dengue virus vaccine oligonucleotide #15.
XX XX ss: cytosstatic; virucide; dengue virus; recombinant replicon; deletion;
XX KW prem protein; C protein; NS1 protein signal; vaccine; cervical cancer;
XX KW viral disease; antigen; dendritic cell; immune response;
XX KW human papillomavirus.
XX XX

```

```

OS Unidentified.
XX XX WO2004072274-A1.
XX XX 26-AUG-2004.
XX XX 30-JAN-2004; 2004WO-CN000088.
XX XX 30-JAN-2003; 2003CN-00115272.
XX XX 30-JAN-2003; 2003CN-00115273.
XX XX (SHAN-) SHANGHAI TENGGEN BIOMEDICAL CO LTD.
XX XX (TENG-) TENGGEN BIOMEDICAL CO.
XX XX (BEIJ-) BEIJING ORIENTAL TENGGEN TECHNOLOGY DEV C.
XX XX Pang X;
XX XX WPI; 2004-625870/60.
XX XX
XX FT Virus-like particle vaccines containing dengue virus recombinant replicon
XX FT as core for carrier, applicable in preventives or/and remedies for tumors
XX FT like cervical cancer and viral diseases.
XX PS Example 4; SEQ ID NO 37; 38pp; Chinese.
XX CC A dengue virus recombinant replicon has a deletion of the complete coding
XX CC sequence for preM protein of dengue virus and also includes elements of
XX CC e.g. the non-coding region in the whole of the 5'-end, the coding region
XX CC of the front 20 amino acids in the C protein, and the coding region of
XX CC NS1 protein signal; coding regions of all non-structural proteins. The
XX CC obtained vaccines are useful in producing preventives or/and remedies for
XX CC cancer like cervical cancer and viral diseases. Such vaccines can
XX CC efficiently express antigen in infected cells, which is because dengue
XX CC virus can infect dendritic cells, and can effectively present antigen to
XX CC provide immunity effect. Different types of dengue virus can be used to
XX CC repeatedly produce efficient immune response thereby strengthening the
XX CC body's immune system against the pathogen that contains such antigen.
XX CC Human papillomavirus (HPV) vaccines were prepared by using a gene-
XX CC expressing system using of the full-length dengue virus cDNA clone
XX CC (P8S/PLD2). The recombinant virus vectors were transfected into baby
XX CC hamster kidney (BHK) cells to enable the screening of BHK-21 ret-off cell
XX CC lines. This sequence corresponds to an oligonucleotide used in the
XX CC recombinant replicon of the invention.
XX SQ Sequence 48 BP; 5 A; 19 C; 15 G; 9 T; 0 U; 0 Other;
XX
Query Match 42.8%; Score 24.4; DB 13; Length 48;
Best Local Similarity 59.4%; Pred. No. 33;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
Qy 4 UCCACCUCCUGCGGNNNNNUGGCAUGCG 35
Db 17 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 48
RESULT 7
ADT48965
ID ADT48965 standard; DNA; 48 BP.
XX AC ADT48965;
XX XX
DT 16-DEC-2004 (first entry)
XX XX PCR primer 5' HDVr, seq id 29.
XX XX Virucide; Japanese encephalitis B virus; bivalent vaccine; hepatitis B;
XX KW PCR; primer; ss.
XX XX Viruses.
XX XX
XX PN WO2004082712-A1.
XX XX 30-SEP-2004.
XX PD

```


XX PF 19-MAR-2004; 2004WO-CN000232.
 XX XX 20-MAR-2003; 2003CN-00115912.
 XX XX (SHAN-) SHANGHAI TENGGEN BIOMEDICAL CO LTD.
 XX XX (TENG-) TENGGEN BIOMEDICAL CO.
 XX XX (BEIJ-) BEIJING ORIENTAL TENGGEN TECHNOLOGY DEV C.
 XX PI Pang X;
 XX DR WPI; 2004-699719/68.
 XX DR Bivalent vaccines for preventing and treating Japanese (B) encephalitis
 PT and hepatitis B produced by recombinant technique using encephalitis B
 PT virus as vector to express antigen gene of hepatitis B.
 XX PS Example 8; SEQ ID NO 29; 33pp; Chinese.
 XX CC The invention relates to a recombinant Japanese encephalitis B virus
 CC constructed from encephalitis B virus and a recombinant genome, where the
 CC genome is inserted with an exogenous nucleotide sequence for
 CC recombination and capable of retaining its self-replication function. The
 CC virus is useful in producing the bivalent vaccines for preventing and
 CC treating Japanese (B) encephalitis and hepatitis B. Such vaccines are
 CC producible at low cost and have high immunoefficacy, in which the
 CC recombinant virus can efficiently express the antigen of hepatitis B
 CC virus with the safety and immunogenicity of attenuated encephalitis B
 CC virus vaccines. The current sequence represents a PCR primer used in an
 CC example from the invention.
 XX XX Sequence 48 BP; 5 A; 19 C; 15 G; 9 T; 0 U; 0 Other;
 . Query Match 42.8%; Score 24.4; DB 13; Length 48;
 Best Local Similarity 59.4%; Pred. No. 33;
 Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
 QY 4 UCCACCUCUCCGCGGUNNNNNUGGCAUCG 35
 :||||:||||: :||||: ||
 Db 17 TCCACCTCTCGGCGTCCGACCTGGGCATCCG 48
 RESULT 8
 AAQ86173
 ID AAQ86173 standard; DNA; 51 BP.
 AC AAQ86173;
 XX 25-MAR-2003 (revised)
 DT 21-NOV-1995 (first entry)
 XX Primer HDV17-68 amplifies vector DNA to initiate Sindbis infection.
 DE Eukaryotic layered vector initiation system; Sindbis; alphavirus; PCR;
 XX transcription initiation; non-structural protein; subgenomic fragment;
 KW RNA polymerase recognition sequence; ELVIS; gene therapy; amplify;
 KW primer; polymerase chain reaction; cystic fibrosis; ss.
 XX OS Synthetic.
 XX WO9507994-A2.
 XX 23-MAR-1995.
 XX 15-SEP-1994; 94WO-US010469.
 XX 15-SEP-1993; 93US-00122791.
 PR 18-FEB-1994; 94US-00198450.
 XX (VIAG-) VIAGENE INC.
 PA Dubensky TW, Ibanez CE, Chang SM, Jolly DJ, Driver DA, Polo JM;
 XX WPI; 1995-131362/17.
 XX New alpha virus vectors for gene therapy - of viral infection, cancer,
 auto:immune disease, etc., and as vaccines.
 XX Example 7; Page 114; 260pp; English.
 XX The sequences given in AAQ86200-15 are primers which were used in the
 production of alphavirus vectors expressing multiple heterologous genes.
 CC These vectors are eukaryotic layered vector initiation systems (ELVIS)

DR WPI; 1995-131362/17.
 XX New alpha virus vectors for gene therapy - of viral infection, cancer,
 auto:immune disease, etc., and as vaccines.
 XX Example 2; Page 68; 260pp; English.
 XX The sequences given in AAQ86167-81 are primers which were used in the
 generation of plasmid DNA which initiates Sindbis infection. The
 CC amplified DNA sequences were used in the construction of a eukaryotic
 CC layered vector initiation system (ELVIS) derived from Sindbis. ELVIS's
 CC comprise a 5' sequence capable of initiating transcription of an
 CC alphavirus, a nucleotide sequence encoding alphavirus non-structural
 CC proteins, a viral junction region which has been inactivated such that
 CC viral transcription of the subgenomic fragment is prevented, and an
 CC alphavirus RNA polymerase recognition sequence. Inactivation of the viral
 CC junction region prevents transcription of the subgenomic fragment making
 CC vectors such as this suitable for a wide variety of applications, eg.
 CC gene therapy for the treatment of cystic fibrosis. (Updated on 25-MAR-
 CC 2003 to correct PN field.)
 XX XX Sequence 51 BP; 9 A; 20 C; 14 G; 8 T; 0 U; 0 Other;
 SQ Query Match 42.8%; Score 24.4; DB 2; Length 51;
 Best Local Similarity 59.4%; Pred. No. 33;
 Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
 QY 4 UCCACCUCUCCGCGGUNNNNNUGGCAUCG 35
 :||||:||||: :||||: ||
 Db 1 TCCACCTCTCGGCGTCCGACCTGGGCATCCG 32
 RESULT 9
 AAQ86204
 ID AAQ86204 standard; DNA; 52 BP.
 XX AAQ86204;
 XX 25-MAR-2003 (revised)
 DT 23-NOV-1995 (first entry)
 XX Sindbis/HDV ribozyme sequence reverse primer, HDV17-68.
 DE Eukaryotic layered vector initiation system; Sindbis; alphavirus; PCR;
 XX transcription initiation; non-structural protein; subgenomic fragment;
 KW RNA polymerase recognition sequence; ELVIS; gene therapy; amplify;
 KW primer; polymerase chain reaction; cystic fibrosis; ss.
 XX OS Synthetic.
 XX WO9507994-A2.
 XX 23-MAR-1995.
 XX 15-SEP-1994; 94WO-US010469.
 XX 15-SEP-1993; 93US-00122791.
 PR 18-FEB-1994; 94US-00198450.
 XX (VIAG-) VIAGENE INC.
 PA Dubensky TW, Ibanez CE, Chang SM, Jolly DJ, Driver DA, Polo JM;
 XX WPI; 1995-131362/17.
 XX New alpha virus vectors for gene therapy - of viral infection, cancer,
 auto:immune disease, etc., and as vaccines.
 XX Example 7; Page 114; 260pp; English.
 XX The sequences given in AAQ86200-15 are primers which were used in the
 production of alphavirus vectors expressing multiple heterologous genes.
 CC These vectors are eukaryotic layered vector initiation systems (ELVIS)

CC derived from Sindbis. ELVIS's comprise a 5' sequence capable of
 CC initiating transcription of an alphavirus, a nucleotide sequence encoding
 CC alphavirus non-structural proteins, a viral junction region which has
 CC been inactivated such that viral transcription of the subgenomic fragment
 CC is prevented, and an alphavirus RNA polymerase recognition sequence.
 CC inactivation of the viral junction region prevents transcription of the
 CC subgenomic fragment making vectors such as this suitable for a wide
 CC variety of applications, eg. gene therapy for the treatment of cystic
 CC fibrosis. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;

Query Match 42.8%; Score 24.4; DB 2; Length 52;
 Best Local Similarity 59.4%; Pred. No. 33;
 Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNNUGGGCAUGCG 35
 :||||:||||: :||||: ||
 Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 10
 AAT31151
 ID AAT31151 standard; DNA; 52 BP.

XX AAT31151;

DT 12-SEP-1996 (first entry)

DE HDV reverse primer HDV17-68.

XX Alphavirus; Sindbis virus; vector; gene therapy; vaccine;
 KW polymerase chain reaction; PCR; primer; hepatitis delta virus; HDV;
 KW ribozyme; ss.

XX Synthetic.

PN WO9617072-A2.

PD 06-JUN-1996.

XX 30-NOV-1995; 95WO-US015490.

XX 30-NOV-1994; 94US-00348472.

PR 18-JAN-1995; 95US-00376184.

PR 15-MAR-1995; 95US-00405827.

XX (CHIR) CHIRON VIAGENE INC.

XX Dubensky TW, Polo JM, Ibanez CE, Chang SMW, Jolly DJ, Driver DA;
 PI Belli BA;

XX WPI; 1996-277785/28.

XX New recombinant alpha-virus vectors - used to develop prods and methods
 PT for use in gene therapy and in the prodn. of vaccines.

XX Example 7; Page 120; 256pp; English.

XX Primer HDV17-68 (AAT31151) is based on hepatitis delta virus (HDV)
 CC nucleotides 839-887. It was used with reverse primer HDV49-XC (AAT30850)
 CC for the PCR amplification of HDV sequences. A second primer pair, SIN-HDV
 CC (AAT31152) and SIN276-SPE (AAT31153), is used to amplify a fragment
 CC contg. Sindbis 5'-end sequences fused to HDV sequences. Overlapping
 CC synthesis is used in a second round of PCR using primers HDV49-XC and
 CC SIN276-SPE. The resulting construct contains the expression cassette
 CC elements HDV ribozyme/Sindbis 5'-end 299 nts/Sindbis junction
 CC region/Sindbis structural protein genes/Sindbis 3'-end untranslated
 CC line, designated pd5'268. This was inserted into pcDNA3. Packaging cell
 CC line cassettes were constructed that allow inducible expression of
 CC structural proteins via alphavirus vectors

XX Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;

Query Match 42.8%; Score 24.4; DB 2; Length 52;
 Best Local Similarity 59.4%; Pred. No. 33;
 Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNNUGGGCAUGCG 35
 :||||:||||: :||||: ||
 Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 11
 AAT30817

ID AAT30817 standard; DNA; 52 BP.

XX AAT30817;

DT 12-SEP-1996 (first entry)

DE HDV ribozyme primer HDV17-68.

XX Alphavirus; Sindbis virus; vector; gene therapy; vaccine; primer;
 KW polymerase chain reaction; PCR; ELVIS; ribozyme; HDV;
 KW hepatitis delta virus; ss.

XX Synthetic.

PN WO9617072-A2.

PD 06-JUN-1996.

XX 30-NOV-1995; 95WO-US015490.

XX 30-NOV-1994; 94US-00348472.

PR 18-JAN-1995; 95US-00376184.

PR 15-MAR-1995; 95US-00405827.

XX (CHIR) CHIRON VIAGENE INC.

XX Dubensky TW, Polo JM, Ibanez CE, Chang SMW, Jolly DJ, Driver DA;
 PI Belli BA;

XX WPI; 1996-277785/28.

XX New recombinant alpha-virus vectors - used to develop prods and methods
 PT for use in gene therapy and in the prodn. of vaccines.

XX Example 3; Page 85; 256pp; English.

XX Primer SHDV1F (AAT30816) contains a buffer sequence allowing enzyme
 CC digestion, a SacI site, and a hepatitis delta virus (HDV) ribozyme
 CC sequence. It was used with nested primer HDV17-68 (AAT30817) and reverse
 CC primer SHDV84R (AAT30818) to generate an HDV ribozyme. This antigenomic
 CC ribozyme can be placed between the polyA tract at the 3' end of a Sindbis
 CC virus-based eukaryotic layered vector initiation system, ELVIS, and the
 CC transcription terminal signals to produce alphavirus expression vectors
 CC useful in methods of gene therapy and for vaccine prodn

XX Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;

Query Match 42.8%; Score 24.4; DB 2; Length 52;
 Best Local Similarity 59.4%; Pred. No. 33;
 Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 4 UCCACCUCCUGCGGUNNNNNNUGGGCAUGCG 35
 :||||:||||: :||||: ||
 Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32

RESULT 12
 AAV42394

ID AAV42394 standard; DNA; 52 BP.

XX AAV42394;

```

XX DT 02-OCT-1998 (first entry)
XX DE Nested PCR primer HDV17-68 of the invention.
XX KW DNA alphavirus; structural protein expression; inhibit; pathogen;
XX KW immune response; stimulate; PCR primer; ss.
XX OS Synthetic.
XX PN US5789245-A.
XX PD 04-AUG-1998.
XX PF 30-OCT-1996; 96US-00741881.
XX PR 15-SEP-1993; 93US-00122791.
XX PR 18-FEB-1994; 94US-00198450.
XX PR 30-NOV-1994; 94US-00348472.
XX PR 20-JAN-1995; 95US-00376184.
XX PR 15-MAR-1995; 95US-00404796.
XX PA (CHIR ) CHIRON CORP.
XX PI Chang SMW, Ibanez CE, Jolly DJ, Dubensky TW, Driver DA, Polo JM;
XX WPI; 1998-446089/38.
XX PT DNA alpha:virus structural protein expression cassettes - for producing
XX PT recombinant alpha:virus particles.
XX PS Example 3; Col 69; 140pp; English.
XX CC PCR primers AAV42367-420 and AAV42422-54 are used in the course of the
XX CC invention. The specification describes a DNA alphavirus structural
XX CC protein expression cassette which comprises an inducible promoter and an
XX CC alphavirus structural protein gene, where the promoter directs the
XX CC expression of the alphavirus structural protein gene upon induction of
XX CC the promoter within a cell, and where prior to induction within the cell,
XX CC the expression cassette does not express sufficient quantities of
XX CC structural proteins to be cytotoxic to a BHK cell containing the
XX CC expression cassette. The products may be used to inhibit pathogens and
XX CC stimulate an immune response
XX SQ Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;

Query Match 42.8%; Score 24.4; DB 2; Length 52;
Best Local Similarity 59.4%; Pred. No. 33;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 4 UCCACCUCCUGCGGUNNNNNNUGGCAUGCG 35
   :|||||:|||||:|||||:|||||:
Db 1 TCCACCTCTCGCGTCCGACCTGGGCATCCG 32

RESULT 13
AAV42426
ID AAV42426 standard; DNA; 52 BP.
XX AC AAV42426;
XX DT 02-OCT-1998 (first entry)
XX DE Forward PCR primer HDV17-68.
XX KW DNA alphavirus; structural protein expression; inhibit; pathogen;
XX KW immune response; stimulate; PCR primer; ss.
XX OS Synthetic.
XX PN US5789245-A.
XX PD 04-AUG-1998.

```

```

XX PF 30-OCT-1996; 96US-00741881.
XX PR 15-SEP-1993; 93US-00122791.
XX PR 18-FEB-1994; 94US-00198450.
XX PR 30-NOV-1994; 94US-00348472.
XX PR 20-JAN-1995; 95US-00376184.
XX PR 15-MAR-1995; 95US-00404796.
XX PA (CHIR ) CHIRON CORP.
XX PI Chang SMW, Ibanez CE, Jolly DJ, Dubensky TW, Driver DA, Polo JM;
XX WPI; 1998-446089/38.
XX PT DNA alpha:virus structural protein expression cassettes - for producing
XX PT recombinant alpha:virus particles.
XX PS Example 7; Col 103; 140pp; English.
XX CC PCR primers AAV42367-420 and AAV42422-54 are used in the course of the
XX CC invention. The specification describes a DNA alphavirus structural
XX CC protein expression cassette which comprises an inducible promoter and an
XX CC alphavirus structural protein gene, where the promoter directs the
XX CC expression of the alphavirus structural protein gene upon induction of
XX CC the promoter within a cell, and where prior to induction within the cell,
XX CC the expression cassette does not express sufficient quantities of
XX CC structural proteins to be cytotoxic to a BHK cell containing the
XX CC expression cassette. The products may be used to inhibit pathogens and
XX CC stimulate an immune response
XX SQ Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;

Query Match 42.8%; Score 24.4; DB 2; Length 52;
Best Local Similarity 59.4%; Pred. No. 33;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 4 UCCACCUCCUGCGGUNNNNNNUGGCAUGCG 35
   :|||||:|||||:|||||:|||||:
Db 1 TCCACCTCTCGCGTCCGACCTGGGCATCCG 32

RESULT 14
AAV60154
ID AAV60154 standard; DNA; 52 BP.
XX AC AAV60154;
XX DT 25-MAR-2003 (revised)
XX DT 04-DEC-1998 (first entry)
XX DE Nested PCR primer HDV17-68.
XX KW Eukaryotic layered vector initiation system; stimulate; immune response;
XX KW Sindbis; PCR primer; ss.
XX OS Synthetic.
XX OS Hepatitis D virus.
XX PN US5814482-A.
XX PD 29-SEP-1998.
XX PF 30-OCT-1996; 96US-00739158.
XX PR 15-SEP-1993; 93US-00122791.
XX PR 18-FEB-1994; 94US-00198450.
XX PR 14-SEP-1994; 94WO-US010469.
XX PR 30-NOV-1994; 94US-00348472.
XX PR 18-JAN-1995; 95US-00376184.
XX PR 15-MAR-1995; 95US-00404796.
XX PA (POLO/) POLO J M.

```

```
PA (DUBE//) DUBENSKY T W.
PA (JOLLY//) JOLLY D J.
PA (DRIV//) DRIVER D A.
XX
PI Driver DA, Polo JM, Jolly DJ, Dubensky TW;
XX
XX WPI; 1998-541753/46.
XX
XX Eukaryotic layered vector initiation system - containing eukaryotic
PT promoter and heterologous antigen coding sequence, useful for stimulating
PT immune response.
XX
XX Example 3; Col 71-72; 144pp; English.
XX
XX PCR primers AAV60153-55 are used to amplify Hepatitis delta virus
CC ribozyme sequence. The product is used in the course of the invention.
CC The specification describes an eukaryotic layered vector initiation
CC system, based on Sindbis. The eukaryotic layered vector initiation
CC comprises a eukaryotic promoter 5' of viral cDNA which initiates, in a
CC susceptible target cell, 5' to 3' synthesis of RNA from the viral cDNA.
CC The RNA comprises a vector construct which autonomously amplifies in the
CC cell and expresses a heterologous nucleic acid sequence which encodes an
CC antigen or modified form that stimulates an immune response within an
CC animal. The system is useful for stimulating an immune response to an
CC antigen by introducing the vector into target cells, preferably by
CC infection in vivo, especially where the immune response is a cell
CC mediated, HLA class I-restricted or an HLA class II-restricted immune
CC response. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;
SQ
Query Match 42.8%; Score 24.4; DB 2; Length 52;
Best Local Similarity 59.4%; Pred. No. 33;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
Qy 4 UCCACCCUCCGCGGUNNNNNNUGGCGCAUGCG 35
Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32
RESULT 15
AAV60185
ID AAV60185 standard; DNA; 52 BP.
XX
XX AAV60185;
AC
XX 25-MAR-2003 (revised)
DT 04-DEC-1998 (first entry)
XX
XX Reverse PCR primer HDV17-68.
DE
XX Eukaryotic layered vector initiation system; stimulate; immune response;
KW Sindbis; PCR primer; ss.
XX
XX Synthetic.
OS
XX US5814482-A.
PN
XX 29-SEP-1998.
PD
XX 30-OCT-1996; 96US-00739158.
PF
XX 15-SEP-1993; 93US-00122791.
PR 18-FEB-1994; 94US-00198450.
PR 14-SEP-1994; 94WO-US010469.
PR 30-NOV-1994; 94US-00348472.
PR 18-JAN-1995; 95US-00376184.
PR 15-MAR-1995; 95US-00404796.
XX
XX (POLO//) POLO J M.
PA (DUBE//) DUBENSKY T W.
PA (JOLLY//) JOLLY D J.
PA (DRIV//) DRIVER D A.
```

```
XX
PI Driver DA, Polo JM, Jolly DJ, Dubensky TW;
XX
XX WPI; 1998-541753/46.
XX
XX Eukaryotic layered vector initiation system - containing eukaryotic
PT promoter and heterologous antigen coding sequence, useful for stimulating
PT immune response.
XX
XX Example 5; Col 108; 144pp; English.
XX
XX PCR primers AAV60184-85 are used in the course of the invention. The
CC specification describes an eukaryotic layered vector initiation system,
CC based on Sindbis. The eukaryotic layered vector initiation system
CC comprises a eukaryotic promoter 5' of viral cDNA which initiates, in a
CC susceptible target cell, 5' to 3' synthesis of RNA from the viral cDNA.
CC The RNA comprises a vector construct which autonomously amplifies in the
CC cell and expresses a heterologous nucleic acid sequence which encodes an
CC antigen or modified form that stimulates an immune response within an
CC animal. The system is useful for stimulating an immune response to an
CC antigen by introducing the vector into target cells, preferably by
CC infection in vivo, especially where the immune response is a cell
CC mediated, HLA class I-restricted or an HLA class II-restricted immune
CC response. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 52 BP; 9 A; 21 C; 14 G; 8 T; 0 U; 0 Other;
SQ
Query Match 42.8%; Score 24.4; DB 2; Length 52;
Best Local Similarity 59.4%; Pred. No. 33;
Matches 19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
Qy 4 UCCACCCUCCGCGGUNNNNNNUGGCGCAUGCG 35
Db 1 TCCACCTCTCGCGGTCCGACCTGGGCATCCG 32
```

Search completed: October 29, 2005, 08:21:09
Job time : 455 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 29, 2005, 02:35:43 ; Search time 1993 Seconds
(without alignments)
724.913 Million cell updates/sec

Title: US-09-699-667E-61
Perfect score: 57
Sequence: 1 ggguccaccuccgagggun.....uucgcauggcuaggagacc 57

Scoring table: IDENTITY NUC
Gapox 10.0, Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 2048674

Minimum DB seq length: 0
Maximum DB seq length: 150

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:
1: gb_est1:*
2: gb_est2:*
3: gb_hic:*
4: gb_est3:*
5: gb_est4:*
6: gb_est5:*
7: gb_est6:*
8: gb_gss1:*
9: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	24	42.1	123	1	AU077016
C 2	21.6	37.9	129	8	AZ937579 2M0195L18
C 3	21.2	37.2	141	4	B1007258 MRI-RT007
C 4	21.2	37.2	147	1	AA094039 cl1641.se
C 5	21	36.8	148	2	BF368659 QV1-GN006
C 6	20.6	36.1	114	1	AV848738 AV848738
C 7	20.6	36.1	117	9	BX907242 Leishmani
C 8	20.6	36.1	117	9	BX543887 Leishmani
C 9	20.6	36.1	118	1	AV855799 AV855799
C 10	20.6	36.1	135	8	CC043330 3591_1_15
C 11	20.2	35.4	109	2	BF875943 CMO-ET016
C 12	20.2	35.4	118	2	BE595364 P11_53.C0
C 13	20.2	35.4	125	1	AA856004 vw81f01.r
C 14	20.2	35.4	144	6	CD863939 AZ01.108J
C 15	20.2	35.4	147	6	CD863940 AZ01.108J
C 16	20	35.1	137	1	AA207969 mv95f06.r
C 17	20	35.1	143	8	AZ407850 1M0178F14
C 18	19.8	34.7	61	7	CN482613 hw22e05.Y
C 19	19.8	34.7	105	8	BH215680 1006028B0
C 20	19.8	34.7	108	2	AW401242 Landigest
C 21	19.8	34.7	135	7	CQ989014 UMC-pd3ten
C 22	19.8	34.7	145	8	B2199525 CH230-444
C 23	19.6	34.4	112	4	BM286935 527162 MA
C 24	19.6	34.4	119	8	BH173238 0011B5 ma

C 25	19.6	34.4	123	4	BG693687	BG693687 344175 BA
C 26	19.6	34.4	136	8	BH035997	BH035997 RPCI-24-3
C 27	19.6	34.4	140	8	CC019353	CC019353 3591_1_14
C 28	19.6	34.4	146	4	BM746675	BM746675 K-EST0021
C 29	19.4	34.0	49	1	AI956143	AI956143 wt35e01.x
C 30	19.4	34.0	117	4	BI021544	BI021544 CM3-MT034
C 31	19.4	34.0	117	4	BI026587	BI026587 CM4-MT028
C 32	19.4	34.0	147	2	BF788210	BF788210 PM1-CR010
C 33	19.4	34.0	150	8	BH220875	BH220875 1006097G0
C 34	19.2	33.7	110	4	BM100180	BM100180 EBma01_SQ
C 35	19.2	33.7	116	4	BM029915	BM029915 488333 MA
C 36	19	33.3	111	7	CO788089	CO788089 NT003B A0
C 37	19	33.3	120	1	AI153878	AI153878 ud50b05.r
C 38	19	33.3	129	1	AA471148	AA471148 PM2267.K
C 39	19	33.3	136	8	BH616926	BH616926 SALU_0356
C 40	19	33.3	140	1	AV847196	AV847196 AV847196
C 41	19	33.3	148	2	BB482390	BB482390 BB482390
C 42	19	33.3	149	2	BE362950	BE362950 DGL_91.A0
C 43	18.8	33.0	73	4	EG035546	EG035546 603255G05
C 44	18.8	33.0	85	6	CD036231	CD036231 mgmtCOL1X1
C 45	18.8	33.0	90	8	AZ307919	AZ307919 1M0010D21

ALIGNMENTS

RESULT 1
AU077016/c
LOCUS AU077016 123 bp mRNA linear EST 04-MAY-2000
DEFINITION AU077016 Sugano cDNA library Homo sapiens cDNA clone Rp-A0037 similar to 5'-end region of Human aminoacylase-1 (ACV1) mRNA, mRNA sequence.

ACCESSION AU077016
VERSION AU077016.1 GI:7439584
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 123)
AUTHORS Suzuki, Y., Ishihara, D., Sasaki, M., Nakagawa, H., Hata, H., Tsunoda, T., Watanabe, M., Komatsu, T., Oka, T., Isogai, T., Suyama, A.

TITLE Statistical analysis of the 5' untranslated region of human mRNA using 'Oligo-Capped' cDNA libraries
JOURNAL Genomics 64 (3), 286-297 (2000)
MEDLINE 20221373
PubMed 10756096

COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: yuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and Sugano, S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997)
This clone was obtained from a 'full length-enriched' cDNA library constructed by 'Oligo-Capping' method. The coding region starts from the 50 bp upstream to the 3'-end.

FEATURES
source 1.123
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="Rp-A0037"
/clone_lib="Sugano cDNA library"

ORIGIN
Query Match 42.1%; Score 24; DB 1; Length 123;
Best Local Similarity 50.0%; Pred. No. 5.8e+02;
Matches 23; Conservative 7; Mismatches 16; Indels 0; Gaps 0;


```
ACCESSION AA094039
VERSION AA094039.1 GI:1639624
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 147)
AUTHORS Liaw,C.C.
TITLE cDNAs from fetal heart (1996)
JOURNAL Unpublished (1996)
COMMENT Contact: Liaw CC
Brigham and Women's Hospital
Harvard Medical School
75 Francis St. Boston, MA 02115, USA
Tel: 6177328915
Fax: 6179750995
Email: cliaw@rics.bwh.harvard.edu
PCR Primers
FORWARD: 5' GCCAAGCTCGAAATTAACCTCCTACTAAAGG 3'
BACKWARD: 5' CCAGTGAATTGTAATCAGCTCCTATAGGCG 3'
Seq primer: 5' GAAATTAACCTCCTACTAAAGG 3'.
FEATURES             source
    Location/Qualifiers
        1..147
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /lab_hosts="E. coli XL1-Blue"
            /clone_lib="Human fetal heart, Lambda ZAP Express"
            /notes="Vector: Lambda ZAP Express; Site_1: EcoRI; Site_2:
            XhoI; mRNA was purified from human fetal hearts (8-10
            weeks). cDNA was synthesized using a XhoI-Oligo dT
            adaptor-primer. EcoRI adaptors were ligated, followed by
            digestion with XhoI, for directional cloning into
            predigested lambda ZAP Express."

ORIGIN
Query Match      37.2%; Score 21.2; DB 1; Length 147;
Best Local Similarity 52.1%; Pred. No. 5.6e+03;
Matches 25; Conservative 4; Mismatches 19; Indels 0; Gaps 0;

QY 7 ACCUCCUGCGGNNNNNUGGCAUGCGGCUUGCAUGGCUAAGGGA 54
    |||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 115 ACCTCTCGCGATTTTGGCTGGCACTCCGCGGCTCATGCCAATAGGA 68

RESULT 5
BF368659/c
LOCUS QV1-GN0063-290800-347-c02_1 GN0063 Homo sapiens cDNA, mRNA
DEFINITION QV1-GN0063-290800-347-c02_1 GN0063 Homo sapiens cDNA, mRNA
sequence.
ACCESSION BF368659
VERSION BF368659.1 GI:11330684
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 148)
AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V.,
O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
PUBMED 10737800
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
```

```
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=QV1&t2=QV1-GN0063-
290800-347-c02_1&t3=2000-08-29&t4=1)
Seq primer: puc 18 forward
High quality sequence stop: 148.
FEATURES             source
    Location/Qualifiers
        1..148
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /dev_stage="Adult"
            /clone_lib="GN0063"
            /notes="Organ: placenta normal; Vector: puc18; Site_1:
            SmaI; Site_2: SmaI; A mini-library was made by cloning
            products derived from ORESTES PCR (U.S. Letters Patent
            application No. 196,716 - Ludwig Institute for Cancer
            Research) profiles into the pUC 18 vector. Reverse
            transcription of tissue mRNA and cDNA amplification were
            performed under low stringency conditions."

ORIGIN
Query Match      36.8%; Score 21; DB 2; Length 148;
Best Local Similarity 43.1%; Pred. No. 6.5e+03;
Matches 22; Conservative 8; Mismatches 21; Indels 0; Gaps 0;

QY 3 GUCCACUCCUCCGCGGNNNNNUGGCAUGCGGCUUGCAUGGCUAAGG 53
    |||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 137 GTCACCTCCAGGTGTGTTCTCTGAAGATGCTTGTTACTATGCTAAGAG 87

RESULT 6
AV848738/c
LOCUS AV848738 Nori Satoh unpublished cDNA library, young adult Ciona
DEFINITION AV848738 Nori Satoh unpublished cDNA library, young adult Ciona
sequence.
ACCESSION AV848738
VERSION AV848738.1 GI:16930368
KEYWORDS EST.
SOURCE Ciona intestinalis
ORGANISM Ciona intestinalis
Eukaryota; Metazoa; Chordata; Urochordata; Ascidiacea; Enterogona;
Phlebobranchia; Clonidae; Ciona.
REFERENCE 1 (bases 1 to 114)
AUTHORS Satoh,N., Satou,Y., Kohara,Y. and Shin-i,T.
TITLE Expressed genes in Ciona intestinalis
JOURNAL Unpublished (2000)
COMMENT Contact: Nori Satoh
Department of Zoology
Kyoto University
Sakyo-ku, Kyoto, Kyoto 606-8502, Japan
Tel: 81-75-753-4081
Fax: 81-75-705-1113
Email: satoh@ascidian.zool.kyoto-u.ac.jp.
FEATURES             source
    Location/Qualifiers
        1..114
            /organism="Ciona intestinalis"
            /mol_type="mRNA"
            /db_xref="taxon:7719"
            /clone_lib="rciad14f13"
            /tissue_type="whole animal"
            /dev_stage="young adult"
            /clone_lib="Nori Satoh unpublished cDNA library, young
            adult"

ORIGIN
Query Match      36.1%; Score 20.6; DB 1; Length 114;
Best Local Similarity 48.5%; Pred. No. 8.9e+03;
```


Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?ti=CMO&t2=CMO-ET0163-111100-687-g07&t3=2000-11-11&t4=1)
Seq primer: puc 18 forward
High quality sequence stop: 109.

source
Location/Qualifiers
1. .109
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone_lib="ET0163"
/notes="Organ: lung_tumor; Vector: puc18; Site: Sma1;
Site 2: Sma1; A mini-library was made by cloning products
derived from ORESTES PCR (U.S. Letters Patent application
No. 196,716 - Ludwig Institute for Cancer Research)
profiles into the pUC 18 vector. Reverse transcription of
tissue mRNA and cDNA amplification were performed under
low stringency conditions."

ORIGIN
Query Match 35.4%; Score 20.2; DB 2; Length 109;
Best Local Similarity 53.8%; Pred. No. 1.2e+04;
Matches 21; Conservative 4; Mismatches 14; Indels 0; Gaps 0;
QY 14 CGCGUNNNNNUGGCAUGCGGCUUGCGCAUGCUAAGG 52
||||| : |||||: |||||
Db 9 CGCGGTCTTACTGCAAGCGGGCTTCTTACTGCAAGG 47

RESULT 12
BE595364/c
LOCUS
DEFINITION
P11.53_C03_b1.A002 Pathogen induced 1 (P11) Sorghum bicolor cDNA,
mRNA sequence.
ACCESSION BE595364
VERSION BE595364.1 GI:9850437
KEYWORDS EST.
SOURCE Sorghum bicolor (sorghum)
ORGANISM Sorghum bicolor
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliopsida; Liliopsida; Poales; Poaceae; PACAD
clade; Panicoideae; Andropogoneae; Sorghum.
REFERENCE 1 (bases 1 to 118)
AUTHORS Cordonnier-Pratt, M.-M., Gingle, A., Dean, R., Sudman, M. and
Pratt, L.H.
TITLE An EST database from Sorghum: pathogen-induced plants
JOURNAL Unpublished (2000)
COMMENT Contact: Cordonnier-Pratt MM
Laboratory for Genomics and Bioinformatics
The University of Georgia, Department of Plant Biology
Plant Sciences Building, Rm. 2502, Athens, GA 30602-7271, USA
Tel: 706 542 1860
Fax: 706 583 0210
Email: mmpratt@uga.edu
Sequences have been trimmed to exclude PolyA, vector and regions
below Phred quality 16. The threshold for highest quality sequence
is 20.
Seq primer: JEN REV
High quality sequence stop: 100
POLYA=No.

FEATURES
source
Location/Qualifiers
1. .118
/organism="Sorghum bicolor"
/mol_type="mRNA"
/db_xref="taxon:4558"
/clone_lib="Pathogen induced 1 (P11)"

REFERENCE
1 (bases 1 to 147)
Pooideae; Triticeae; Triticum.
Genoplante.
AUTHORS
Genoplante, a major partnership french program in plant genomics
TITLE
Unpublished (2003)
JOURNAL
Contact: Genoplante
COMMENT
Genoplante
93, rue Henri Rochefort 91025 EVRY CEDEX France
Tel: 33 1 69 47 54 00
Fax: 33 1 69 47 54 10
This sequence has been generated in the framework of the french
plant genomics programme 'Genoplante' (<http://www.genoplante.com>)
and <http://genoplante-info.infobiogen.fr>.

FEATURES
source
1..147
Location/Qualifiers
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="recital"
/db_xref="taxon:4565"
/clone="AZ01108J17"
/tissue_type="leaf"
/clone_lib="AZ01"

ORIGIN

Query Match 35.4%; Score 20.2; DB 6; Length 147;
Best Local Similarity 45.5%; Pred.No.1.2e+04;
Matches 25; Conservative 6; Mismatches 24; Indels 0; Gaps 0;
Qy 3 GUCCACUCCUCCGCGUNNNUGGCGCAUGCGCUUCGCAUGGCUAAGGGACCC 57
Db 25 GTGTCCTCCAGGCCGTCGCGCTCCGCGCTTGGCGAACCGGCC 79

Search completed: October 29, 2005, 09:39:59
Job time : 3002 secs

THIS PAGE BLANK (USPTO)

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	51	89.5	57	6	AX012282	Sequence
2	51	89.5	57	6	AX012283	Sequence
3	51	89.5	57	6	AX012285	Sequence
4	51	89.5	57	6	AX012286	Sequence
5	51	89.5	57	6	AX012287	Sequence
6	51	89.5	57	6	AX012288	Sequence
7	51	89.5	57	6	AX012289	Sequence
8	51	89.5	57	6	AX012290	Sequence
9	41.4	72.6	57	6	AX012284	Sequence
10	31	54.4	37	6	AX012291	Sequence
11	25.8	45.3	61	6	I41390	Sequence 18
12	24.4	42.8	52	6	AR021007	Sequence
13	24.4	42.8	52	6	AR021047	Sequence
14	24.4	42.8	52	6	AR043422	Sequence
15	24.4	42.8	52	6	AR043422	Sequence
16	24.4	42.8	52	6	AR062337	Sequence
17	24.4	42.8	52	6	AR062377	Sequence
18	24.4	42.8	52	6	AR183796	Sequence
19	24.4	42.8	52	6	AR183836	Sequence

REFERENCE	other sequences; artificial sequences.	
AUTHORS	Ananvoranich,S., Lafontaine,D. and Perreault,J.P.	
TITLE	Nucleic acid enzyme for rna cleavage	
JOURNAL	Patent: WO 9955856-A 45 04-NOV-1999; ANANVORANICH SIRINART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN PIERRE (CA); UNIV SHERBROOKE (CA)	
FEATURES	Location/Qualifiers	
source	1..57	
ORIGIN	Query Match 89.5%; Score 51; DB 6; Length 57; Best Local Similarity 71.9%; Pred. No. 4.5e-06; Matches 41; Conservative 10; Mismatches 6; Indels 0; Gaps 0;	
	/organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="synthetic nucleic acid"	
ORIGIN	1 GGUCCACCUCCUGCGGUNNNNNUGGCAUGCGGUCCGCUAAGGGACCC 57 : : : : : : : : : : : Db 1 GGGTCCACCTCTCGCGTCCGCGTGGCATGCGCTTCGCATGGCTAAGGGACCC 57	
RESULT 3		
LOCUS	AX012285 57 bp RNA linear PAT 06-SEP-2000	
DEFINITION	Sequence 47 from Patent WO9955856.	
ACCESSION	AX012285	
VERSION	AX012285.1 GI:9998346	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	
REFERENCE	1	
AUTHORS	Ananvoranich,S., Lafontaine,D. and Perreault,J.P.	
TITLE	Nucleic acid enzyme for rna cleavage	
JOURNAL	Patent: WO 9955856-A 47 04-NOV-1999; ANANVORANICH SIRINART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN PIERRE (CA); UNIV SHERBROOKE (CA)	
FEATURES	Location/Qualifiers	
source	1..57	
ORIGIN	Query Match 89.5%; Score 51; DB 6; Length 57; Best Local Similarity 71.9%; Pred. No. 4.5e-06; Matches 41; Conservative 10; Mismatches 6; Indels 0; Gaps 0;	
	/organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="synthetic nucleic acid"	
ORIGIN	1 GGUCCACCUCCUGCGGUNNNNNUGGCAUGCGGUCCGCUAAGGGACCC 57 : : : : : : : : : : : Db 1 GGGTCCACCTCTCGCGTCCGCGTGGCATGCGCTTCGCATGGCTAAGGGACCC 57	
RESULT 4		
LOCUS	AX012286 57 bp RNA linear PAT 06-SEP-2000	
DEFINITION	Sequence 48 from Patent WO9955856.	
ACCESSION	AX012286	
VERSION	AX012286.1 GI:9998347	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	
REFERENCE	1	
AUTHORS	Ananvoranich,S., Lafontaine,D. and Perreault,J.P.	
TITLE	Nucleic acid enzyme for rna cleavage	
JOURNAL	Patent: WO 9955856-A 48 04-NOV-1999; ANANVORANICH SIRINART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN PIERRE (CA); UNIV SHERBROOKE (CA)	
FEATURES	Location/Qualifiers	
source	1..57	
ORIGIN	Query Match 89.5%; Score 51; DB 6; Length 57; Best Local Similarity 71.9%; Pred. No. 4.5e-06; Matches 41; Conservative 10; Mismatches 6; Indels 0; Gaps 0;	
	/organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="synthetic nucleic acid"	
ORIGIN	1 GGUCCACCUCCUGCGGUNNNNNUGGCAUGCGGUCCGCUAAGGGACCC 57 : : : : : : : : : : : Db 1 GGGTCCACCTCTCGCGTCCGCGTGGCATGCGCTTCGCATGGCTAAGGGACCC 57	
REFERENCE	other sequences; artificial sequences.	
AUTHORS	Ananvoranich,S., Lafontaine,D. and Perreault,J.P.	
TITLE	Nucleic acid enzyme for rna cleavage	
JOURNAL	Patent: WO 9955856-A 48 04-NOV-1999; ANANVORANICH SIRINART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN PIERRE (CA); UNIV SHERBROOKE (CA)	
FEATURES	Location/Qualifiers	
source	1..57	
ORIGIN	Query Match 89.5%; Score 51; DB 6; Length 57; Best Local Similarity 71.9%; Pred. No. 4.5e-06; Matches 41; Conservative 10; Mismatches 6; Indels 0; Gaps 0;	
	/organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="synthetic nucleic acid"	
ORIGIN	1 GGUCCACCUCCUGCGGUNNNNNUGGCAUGCGGUCCGCUAAGGGACCC 57 : : : : : : : : : : : Db 1 GGGTCCACCTCTCGCGTCCGCGTGGCATGCGCTTCGCATGGCTAAGGGACCC 57	
RESULT 5		
LOCUS	AX012287 57 bp RNA linear PAT 06-SEP-2000	
DEFINITION	Sequence 49 from Patent WO9955856.	
ACCESSION	AX012287	
VERSION	AX012287.1 GI:9998348	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	
REFERENCE	1	
AUTHORS	Ananvoranich,S., Lafontaine,D. and Perreault,J.P.	
TITLE	Nucleic acid enzyme for rna cleavage	
JOURNAL	Patent: WO 9955856-A 49 04-NOV-1999; ANANVORANICH SIRINART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN PIERRE (CA); UNIV SHERBROOKE (CA)	
FEATURES	Location/Qualifiers	
source	1..57	
ORIGIN	Query Match 89.5%; Score 51; DB 6; Length 57; Best Local Similarity 71.9%; Pred. No. 4.5e-06; Matches 41; Conservative 10; Mismatches 6; Indels 0; Gaps 0;	
	/organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="synthetic nucleic acid"	
ORIGIN	1 GGUCCACCUCCUGCGGUNNNNNUGGCAUGCGGUCCGCUAAGGGACCC 57 : : : : : : : : : : : Db 1 GGGTCCACCTCTCGCGTCCGCGTGGCATGCGCTTCGCATGGCTAAGGGACCC 57	
RESULT 6		
LOCUS	AX012288 57 bp RNA linear PAT 06-SEP-2000	
DEFINITION	Sequence 50 from Patent WO9955856.	
ACCESSION	AX012288	
VERSION	AX012288.1 GI:9998349	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	
REFERENCE	1	
AUTHORS	Ananvoranich,S., Lafontaine,D. and Perreault,J.P.	
TITLE	Nucleic acid enzyme for rna cleavage	
JOURNAL	Patent: WO 9955856-A 50 04-NOV-1999; ANANVORANICH SIRINART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN PIERRE (CA); UNIV SHERBROOKE (CA)	
FEATURES	Location/Qualifiers	
source	1..57	
ORIGIN	Query Match 89.5%; Score 51; DB 6; Length 57; Best Local Similarity 71.9%; Pred. No. 4.5e-06; Matches 41; Conservative 10; Mismatches 6; Indels 0; Gaps 0;	
	/organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="synthetic nucleic acid"	
ORIGIN	1 GGUCCACCUCCUGCGGUNNNNNUGGCAUGCGGUCCGCUAAGGGACCC 57 : : : : : : : : : : : Db 1 GGGTCCACCTCTCGCGTCCGCGTGGCATGCGCTTCGCATGGCTAAGGGACCC 57	

Db 1 GGGTCCACCTCTCGCGGTCCGATCTCGGCATCGCGCTTCGCATGCTGAAGGGACCC 57

RESULT 9
 LOCUS AX012284 57 bp RNA linear PAT 06-SEP-2000
 DEFINITION Sequence 46 from Patent WO955856.
 ACCESSION AX012284
 VERSION AX012284.1 GI:9998345
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 other sequences; artificial sequences.

REFERENCE 1
 AUTHORS Ananvoranich,S., Lafontaine,D. and Perreault,J.P.
 TITLE Nucleic acid enzyme for rna cleavage
 JOURNAL Patent: WO 955856-A 46 04-NOV-1999;
 ANANVORANICH STRIWART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN
 PIERRE (CA); UNIV SHERBROOKE (CA)
 FEATURES
 source Location/Qualifiers
 1..57
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="synthetic nucleic acid"

ORIGIN
 Query Match 72.6%; Score 41.4; DB 6; Length 57;
 Best Local Similarity 64.9%; Pred. No. 0.0057;
 Matches 37; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

Qy 1 GGGUCCACUCCUCCGCGUNNNNUGGCAUCGCGGCUUGCAUGGCUAAGGGACCC 57
 |||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||
 Db 1 GGGTCCACCTCTCGCGGTCCGATCTCGGCATCGCGCTTCGCATGCTGAAGGGACCC 57

RESULT 10
 LOCUS AX012291 37 bp RNA linear PAT 06-SEP-2000
 DEFINITION Sequence 53 from Patent WO955856.
 ACCESSION AX012291
 VERSION AX012291.1 GI:9998352
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 other sequences; artificial sequences.

REFERENCE 1
 AUTHORS Ananvoranich,S., Lafontaine,D. and Perreault,J.P.
 TITLE Nucleic acid enzyme for rna cleavage
 JOURNAL Patent: WO 955856-A 53 04-NOV-1999;
 ANANVORANICH STRIWART (CA); LAFONTAINE DANIEL (CA); PERREAULT JEAN
 PIERRE (CA); UNIV SHERBROOKE (CA)
 FEATURES
 source Location/Qualifiers
 1..37
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="synthetic nucleic acid"

ORIGIN
 Query Match 54.4%; Score 31; DB 6; Length 37;
 Best Local Similarity 67.6%; Pred. No. 14;
 Matches 25; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

Qy 1 GGGUCCACUCCUCCGCGUNNNNUGGCAUCGCGGCAUGGCGCC 37
 |||:|||:|||:|||:|||:|||:|||:|||:|||:|||
 Db 1 GGGTCCACCTCTCGCGGTCCGATCTCGGCATCGCGCTTCGCATGCTGAAGGGACCC 37

RESULT 11
 LOCUS I41390 61 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 18 from patent US 5625047.

ACCESSION	I41390
VERSION	I41390.1 GI:2081980
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified. 1 (bases 1 to 61)
AUTHORS	Been,M.D., Rosenstein,S.P. and Perrotta,A.T.
TITLE	Enzymatic RNA molecules
JOURNAL	Patent: US 5625047-A 18 29-APR-1997;
FEATURES	Location/Qualifiers source 1..61 /organism="unknown" /mol_type="unassigned DNA"
ORIGIN	
Query Match	45.3%; Score 25.8; DB 6; Length 61;
Best Local Similarity	58.5%; Pred.No. 6.3e+02;
Matches	31; Conservative 10; Mismatches 8; Indels 4; Gaps 1;
Qy	4 UCCACCUCUCCGGGUNNNNUGGCGAUGCAGCGCUCCGAUGGCUAAGGGACC 56 : : : : : : : Db TCCACCTCCTCGCGGTCCGACTGGGCAT---CTTCGGATGGCTAAGGGAGC 56
RESULT 12	
LOCUS	AR021007 52 bp DNA linear PAT 05-DEC-1998
DEFINITION	Sequence 40 from patent US 5789245.
ACCESSION	AR021007
VERSION	AR021007.1 GI:3975622
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 52)
AUTHORS	Dubensky,T.W. Jr., Polo,J.M., Ibanez,C.E., Chang,S.M.W., Jolly,D.J. and Driver,D.A.
TITLE	Alphavirus structural protein expression cassettes
JOURNAL	Patent: US 5789245-A 40 04-AUG-1998;
FEATURES	Location/Qualifiers source 1..52 /organism="unknown" /mol_type="unassigned DNA"
ORIGIN	
Query Match	42.8%; Score 24.4; DB 6; Length 52;
Best Local Similarity	59.4%; Pred.No. 1.8e+03;
Matches	19; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
Qy	4 UCCACCUCUCCGGGUNNNNUGGCGAUGCAGCG 35 : : : : : : Db TCCACCTCCTCGCGGTCCGACTGGGCATCCG 32
RESULT 13	
LOCUS	AR021047 52 bp DNA linear PAT 05-DEC-1998
DEFINITION	Sequence 80 from patent US 5789245.
ACCESSION	AR021047
VERSION	AR021047.1 GI:3975662
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 52)
AUTHORS	Dubensky,T.W. Jr., Polo,J.M., Ibanez,C.E., Chang,S.M.W., Jolly,D.J. and Driver,D.A.
TITLE	Alphavirus structural protein expression cassettes
JOURNAL	Patent: US 5789245-A 80 04-AUG-1998;
FEATURES	Location/Qualifiers source 1..52 /organism="unknown"

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 29, 2005, 08:12:41 ; Search time 3876 Seconds

(without alignments)
600.339 Million cell updates/sec

Title: US-09-699-667E-61

Perfect score: 57

Sequence: 1 ggguccaccucccgcggun.....uucgauggcuaggagacc 57

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 45554873 seqs, 20411521753 residues

Total number of hits satisfying chosen parameters: 41414866

Minimum DB seq length: 0

Maximum DB seq length: 150

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending Patents NA Main:

1: /cgn2_6/ptodata/1/pna/PCTUS1_COMB.seq.*
2: /cgn2_6/ptodata/1/pna/PCTUS2_COMB.seq.*
3: /cgn2_6/ptodata/1/pna/PCTUS3_COMB.seq.*
4: /cgn2_6/ptodata/1/pna/US06_COMB.seq.*
5: /cgn2_6/ptodata/1/pna/US07_COMB.seq.*
6: /cgn2_6/ptodata/1/pna/US08_COMB.seq.*
7: /cgn2_6/ptodata/1/pna/US081_COMB.seq.*
8: /cgn2_6/ptodata/1/pna/US082_COMB.seq.*
9: /cgn2_6/ptodata/1/pna/US083_COMB.seq.*
10: /cgn2_6/ptodata/1/pna/US084_COMB.seq.*
11: /cgn2_6/ptodata/1/pna/US085_COMB.seq.*
12: /cgn2_6/ptodata/1/pna/US086_COMB.seq.*
13: /cgn2_6/ptodata/1/pna/US087_COMB.seq.*
14: /cgn2_6/ptodata/1/pna/US088_COMB.seq.*
15: /cgn2_6/ptodata/1/pna/US089_COMB.seq.*
16: /cgn2_6/ptodata/1/pna/US090_COMB.seq.*
17: /cgn2_6/ptodata/1/pna/US091_COMB.seq.*
18: /cgn2_6/ptodata/1/pna/US092A_COMB.seq.*
19: /cgn2_6/ptodata/1/pna/US092B_COMB.seq.*
20: /cgn2_6/ptodata/1/pna/US093A_COMB.seq.*
21: /cgn2_6/ptodata/1/pna/US093B_COMB.seq.*
22: /cgn2_6/ptodata/1/pna/US094_COMB.seq.*
23: /cgn2_6/ptodata/1/pna/US095A_COMB.seq.*
24: /cgn2_6/ptodata/1/pna/US095B_COMB.seq.*
25: /cgn2_6/ptodata/1/pna/US095C_COMB.seq.*
26: /cgn2_6/ptodata/1/pna/US095D_COMB.seq.*
27: /cgn2_6/ptodata/1/pna/US096A_COMB.seq.*
28: /cgn2_6/ptodata/1/pna/US096B_COMB.seq.*
29: /cgn2_6/ptodata/1/pna/US096C_COMB.seq.*
30: /cgn2_6/ptodata/1/pna/US096D_COMB.seq.*
31: /cgn2_6/ptodata/1/pna/US096E_COMB.seq.*
32: /cgn2_6/ptodata/1/pna/US097A_COMB.seq.*
33: /cgn2_6/ptodata/1/pna/US097B_COMB.seq.*
34: /cgn2_6/ptodata/1/pna/US097C_COMB.seq.*
35: /cgn2_6/ptodata/1/pna/US098A_COMB.seq.*
36: /cgn2_6/ptodata/1/pna/US098B_COMB.seq.*
37: /cgn2_6/ptodata/1/pna/US098C_COMB.seq.*
38: /cgn2_6/ptodata/1/pna/US098D_COMB.seq.*
39: /cgn2_6/ptodata/1/pna/US099A_COMB.seq.*
40: /cgn2_6/ptodata/1/pna/US099B_COMB.seq.*
41: /cgn2_6/ptodata/1/pna/US099C_COMB.seq.*
42: /cgn2_6/ptodata/1/pna/US099D_COMB.seq.*
43: /cgn2_6/ptodata/1/pna/US099E_COMB.seq.*

44: /cgn2_6/ptodata/1/pna/US099F_COMB.seq.*
45: /cgn2_6/ptodata/1/pna/US099G_COMB.seq.*
46: /cgn2_6/ptodata/1/pna/US100A_COMB.seq.*
47: /cgn2_6/ptodata/1/pna/US100B_COMB.seq.*
48: /cgn2_6/ptodata/1/pna/US101A_COMB.seq.*
49: /cgn2_6/ptodata/1/pna/US101B_COMB.seq.*
50: /cgn2_6/ptodata/1/pna/US102A_COMB.seq.*
51: /cgn2_6/ptodata/1/pna/US102B_COMB.seq.*
52: /cgn2_6/ptodata/1/pna/US103A_COMB.seq.*
53: /cgn2_6/ptodata/1/pna/US103B_COMB.seq.*
54: /cgn2_6/ptodata/1/pna/US104A_COMB.seq.*
55: /cgn2_6/ptodata/1/pna/US104B_COMB.seq.*
56: /cgn2_6/ptodata/1/pna/US105A_COMB.seq.*
57: /cgn2_6/ptodata/1/pna/US105B_COMB.seq.*
58: /cgn2_6/ptodata/1/pna/US106A_COMB.seq.*
59: /cgn2_6/ptodata/1/pna/US107A_COMB.seq.*
60: /cgn2_6/ptodata/1/pna/US107B_COMB.seq.*
61: /cgn2_6/ptodata/1/pna/US107C_COMB.seq.*
62: /cgn2_6/ptodata/1/pna/US107D_COMB.seq.*
63: /cgn2_6/ptodata/1/pna/US108A_COMB.seq.*
64: /cgn2_6/ptodata/1/pna/US108B_COMB.seq.*
65: /cgn2_6/ptodata/1/pna/US109A_COMB.seq.*
66: /cgn2_6/ptodata/1/pna/US109B_COMB.seq.*
67: /cgn2_6/ptodata/1/pna/US109C_COMB.seq.*
68: /cgn2_6/ptodata/1/pna/US110_COMB.seq.*
69: /cgn2_6/ptodata/1/pna/US6000_COMB.seq.*
70: /cgn2_6/ptodata/1/pna/US6001_COMB.seq.*
71: /cgn2_6/ptodata/1/pna/US6002_COMB.seq.*
72: /cgn2_6/ptodata/1/pna/US6003_COMB.seq.*
73: /cgn2_6/ptodata/1/pna/US6004_COMB.seq.*
74: /cgn2_6/ptodata/1/pna/US6005_COMB.seq.*
75: /cgn2_6/ptodata/1/pna/US6006_COMB.seq.*
76: /cgn2_6/ptodata/1/pna/US6007_COMB.seq.*
77: /cgn2_6/ptodata/1/pna/US6008_COMB.seq.*
78: /cgn2_6/ptodata/1/pna/US6009_COMB.seq.*
79: /cgn2_6/ptodata/1/pna/US6010_COMB.seq.*
80: /cgn2_6/ptodata/1/pna/US6011_COMB.seq.*
81: /cgn2_6/ptodata/1/pna/US6012_COMB.seq.*
82: /cgn2_6/ptodata/1/pna/US6013_COMB.seq.*
83: /cgn2_6/ptodata/1/pna/US6014_COMB.seq.*
84: /cgn2_6/ptodata/1/pna/US6015_COMB.seq.*
85: /cgn2_6/ptodata/1/pna/US6016_COMB.seq.*
86: /cgn2_6/ptodata/1/pna/US6017_COMB.seq.*
87: /cgn2_6/ptodata/1/pna/US6018_COMB.seq.*
88: /cgn2_6/ptodata/1/pna/US6019_COMB.seq.*
89: /cgn2_6/ptodata/1/pna/US6020_COMB.seq.*
90: /cgn2_6/ptodata/1/pna/US6021_COMB.seq.*
91: /cgn2_6/ptodata/1/pna/US6022_COMB.seq.*
92: /cgn2_6/ptodata/1/pna/US6023A_COMB.seq.*
93: /cgn2_6/ptodata/1/pna/US6023B_COMB.seq.*
94: /cgn2_6/ptodata/1/pna/US6024_COMB.seq.*
95: /cgn2_6/ptodata/1/pna/US6025_COMB.seq.*
96: /cgn2_6/ptodata/1/pna/US6026_COMB.seq.*
97: /cgn2_6/ptodata/1/pna/US6027_COMB.seq.*
98: /cgn2_6/ptodata/1/pna/US6028_COMB.seq.*
99: /cgn2_6/ptodata/1/pna/US6029_COMB.seq.*
100: /cgn2_6/ptodata/1/pna/US6030_COMB.seq.*
101: /cgn2_6/ptodata/1/pna/US6031_COMB.seq.*
102: /cgn2_6/ptodata/1/pna/US6032_COMB.seq.*
103: /cgn2_6/ptodata/1/pna/US6033_COMB.seq.*
104: /cgn2_6/ptodata/1/pna/US6034_COMB.seq.*
105: /cgn2_6/ptodata/1/pna/US6035_COMB.seq.*
106: /cgn2_6/ptodata/1/pna/US6036_COMB.seq.*
107: /cgn2_6/ptodata/1/pna/US6037_COMB.seq.*
108: /cgn2_6/ptodata/1/pna/US6038_COMB.seq.*
109: /cgn2_6/ptodata/1/pna/US6039_COMB.seq.*
110: /cgn2_6/ptodata/1/pna/US6040_COMB.seq.*
111: /cgn2_6/ptodata/1/pna/US6041_COMB.seq.*
112: /cgn2_6/ptodata/1/pna/US6042_COMB.seq.*
113: /cgn2_6/ptodata/1/pna/US6043_COMB.seq.*
114: /cgn2_6/ptodata/1/pna/US6044_COMB.seq.*
115: /cgn2_6/ptodata/1/pna/US6045_COMB.seq.*
116: /cgn2_6/ptodata/1/pna/US6046_COMB.seq.*

THIS PAGE BLANK (USPTO)

117: /cgn2_6/ptodata/1/pna/US6047 COMB.seq.*
118: /cgn2_6/ptodata/1/pna/US6048 COMB.seq.*
119: /cgn2_6/ptodata/1/pna/US6049 COMB.seq.*
120: /cgn2_6/ptodata/1/pna/US6050 COMB.seq.*
121: /cgn2_6/ptodata/1/pna/US6051 COMB.seq.*
122: /cgn2_6/ptodata/1/pna/US6052 COMB.seq.*
123: /cgn2_6/ptodata/1/pna/US6053 COMB.seq.*
124: /cgn2_6/ptodata/1/pna/US6054 COMB.seq.*
125: /cgn2_6/ptodata/1/pna/US6055 COMB.seq.*
126: /cgn2_6/ptodata/1/pna/US6056 COMB.seq.*
127: /cgn2_6/ptodata/1/pna/US6057 COMB.seq.*
128: /cgn2_6/ptodata/1/pna/US6058 COMB.seq.*
129: /cgn2_6/ptodata/1/pna/US6059 COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 29, 2005, 08:21:20 ; Search time 1990 Seconds
(without alignments)
411.830 Million cell updates/sec

Title: US-09-699-667E-61
Perfect score: 57
Sequence: 1 ggguccaccuccgaggun.....uucgcauggcuaggagccc 57

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 27723106 seqs, 7188968421 residues

Total number of hits satisfying chosen parameters: 40003802

Minimum DB seq length: 0
Maximum DB seq length: 150

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending Patents_NA New:
1: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq:
2: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq:
3: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq:
4: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq:
5: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq:
6: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq:
7: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq:
8: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq:
9: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
10: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
11: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
12: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
13: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
14: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
15: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
16: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
17: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
18: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
19: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
20: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
21: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
22: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
23: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
24: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
25: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
26: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
27: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
28: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq:

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match Length	ID	Description
------------	-------	--------------	----	-------------

* Query

THIS PAGE BLANK (USPTO)